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1 Introduction 
To develop and maintain a cohesive and complex biological entity from a single cell, such as 
specialized tissues consisting of billions of cells, necessitates the presence of multiple highly 
orchestrated processes and suitable scaffolds. In mammals, a gradual evolution from the 
zygote to more specialized cells takes place during the process of development (Evans, 
2011), and multiple cells with the capacity to theoretically differentiate into all tissue-specific 
lineages need to evolve. Ernst Haeckel named these cells ‘Stammzelle’ in 1868 from which 
the term ‘stem cells’ has been derived. These stem cells can be classified as having various 
levels of differentiation capabilities depending on the cell types they give rise to. Thus, the 
zygote and the cells of the early blastomere are known as totipotent stem cells and they have 
the ability to generate an entire organism. Next, embryonic stem cells can be obtained from 
the inner cell mass of the blastocyst, are known as pluripotent stem cells, and are capable of 
differentiating into all three germ layers except the trophectoderm, which is extraembryonic 
(Rippon and Bishop, 2004). In contrast, tissue residing stem cells refer to cells that have a 
comparatively limited differentiation capacity, are therefore more specialized, and are called 
multipotent stem cells. They have the capacity to generate various lineages and give rise to 
specific progenitors, e.g. hematopoietic stem cells (HSCs; Eaves, 2015) or mesenchymal 
stem/stromal cells (MSCs; Zuk et al., 2002). Three more stem cell sub-classifications also 
exists, namely, oligopotent stem cells that refer to progenitors and can differentiate into 
subsets of mature tissue specific cells. Unipotent stem cells that can differentiate into only a 
single cell type (de Kretser, 2007), and induced pluripotent stem cells. These latter stem cells 
are artificially reprogramed somatic cells that demonstrate characteristics of pluripotent stem 
cells, including expression of characteristic markers, are capable of forming all three germ 
layers, and can differentiate into different tissues (Yu et al., 2007). Therefore, stem cells, in 
general, are defined as clonogenic cells that are distinguished by their unspecialized self-
renewing phenotype and inducible differentiation capacity.    
 Stem cell division 
Human adult multipotent stem cells are present in nearly all tissues and organs where they 
usually multiply and differentiate to replace or repair the tissue they reside in. However, in 
some cases, stem cells of a specific tissue give rise to cells of a completely different tissue. 
This phenomenon is known as stem cell plasticity. A common source of transdifferentiating 
stem cells is the bone marrow (Quesenberry et al., 2004). Stem cell division occurs due to 
multiple intrinsic and extrinsic factors that are either present or are transported to the 
environment the cells reside in. These factors lead to symmetric or asymmetric division, 
which give rise to two identical (same fate) or two different daughter cells, respectively. For 
example, Self-renewing stem cells divide symmetrically to produce stem cells with the cell 
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fate of the primary cell while asymmetric division results in a stem cell and a more mature 
cell type, such as a progenitor cell (Figure 1-1). In the hematopoietic system, stem cells 
constantly divide to renew blood cells at the rate of more than one million cells per second 
(Ogawa, 1993; Bryder et al., 2006). Therefore, HSCs differentiate to hematopoietic 
progenitor cells (HPCs) that are capable of self-renewal and therefore, give rise to dividing 
cells that multiply the number of repopulating units. Interestingly, stem cells from different 
tissues divide and generate progeny at non-identical rates. Thus, specific tissues can be 
regenerated diverse effectively. As described HSCs and HPCs constantly renew blood 
frequently; however, to activate residing stem cells during brain or heart regeneration, 
specialized conditions are needed (Taupin and Gage, 2002; Beltrami et al., 2003).  
 
Figure 1-1: Stem cell division strategies (adopted from Morrison and Kimble, 2006) 
A) The stem cell population (blue) can either divide by symmetric or asymmetric division. Symmetric 
division leads to siblings with the same cell fate as the dividing cell, i.e. self-renewal. Asymmetric 
division can produce two sets of progeny, i.e., one set with one stem cell and one mature cell or 
another set with two mature cells (orange). (B) Asymmetric division is defined by cell polarity and lead 
to stem cells (blue) or more mature/differentiated cells (orange). Three mechanisms are plausible. I: 
Regulators of cell polarity are asymmetrically distributed along the membrane (dark blue lines). II: Cell 
fate regulators (dark blue circles) are associated with the membrane, the centrosome, or a cell 
compartment that is asymmetrically distributed. III: The mitotic spindle is oriented toward the stem cell 
niche (dark blue area), and thereby regulates the accessibility of only one of the daughter cells to 
extrinsic signals required to maintain stem cell fate. 
 
Asymmetric division, in this context, represents an attractive strategy for stem cells because 
it simultaneously facilitates self-renewal and differentiation. The mechanisms governing 
asymmetric division can be separated into intrinsic signals (fate determinants) that partition 
the dividing cell to assemble polarity (Figure 1-1B I-II) and extrinsic signals that optimize cell 
positioning towards environmental cues that enable polarization (Figure 1-1B II). However, 
asymmetric division represents a major drawback during development (Morrison et al., 1995) 
or stem cell loss after injury (Bodine et al., 1996), as the stem cell pool cannot be expanded 
(Morrison and Kimble, 2006). In such situations, symmetric division can repopulate stem 
cells in the developing embryo or in the stem cell compartment of adults and result in tissue 
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homeostasis (Yang et al., 2015). Moreover, in regenerative medicine regimens that use 
autologous or allogenic stem cell transplantation such as bone marrow (BM) HSC 
transplantation (HSCT), symmetric division of HSCs allows complete reconstitution of the BM 
blood producing compartment.  
An emerging alternative method of generating stem cells is dedifferentiation, where mature 
cells receive signals to reverse their state of differentiation to acquire stem- or progenitor-cell 
properties. This can be facilitated in vitro by inducing the expression of the so-called 
‘Yamanaka factors’ (Oct4, Sox2, cMyc, Klf4). Using a retroviral expression system 
Yamanaka and colleagues could show that induction of these four transcription factors 
resulted in induced pluripotency in human and mouse fibroblasts (Takahashi and Yamanaka, 
2006; Nakagawa et al., 2007; Takahashi et al., 2007). A common in vivo dedifferentiation 
process is known to occur in tumor and tumor stem cell development (Friedmann-Morvinski 
and Verma, 2014), but stem cell plasticity can also be partially mediated by dedifferentiation 
during human tissue development. For example, in the small intestine, the expression of Myc 
is induced by the Wnt/β-Catenin pathway, which could lead to stem cell transformation from 
somatic cells within the tissue (Finch et al., 2009).  
 
Figure 1-2: The stem cell niche (Scadden, 2006) 
The stem cell niche is presented as a local 
environment in tissues. Stem cells (in cyan) are 
influenced and regulated by multiple signals 
including neuronal input, contact with sibling cells 
(light blue and green) and other niche cells (gray) 
as well as metabolic, paracrine, and endocrine 
signals from local or distant sources. Moreover, 
structural constrains and physical cues in the 
extracellular environment are critical factors that 
tightly regulate stem cell systems. 
 
Nevertheless, cell division and differentiation processes are controlled by factors that are 
provided by a specialized microenvironment where the stem cells reside. This environment is 
called the stem cell niche. This niche comprises cellular and extracellular features that 
orchestrate stem cell function using paracrine and metabolic signals or physical and 
structural cues, as depicted in Figure 1-2.  
1.1 The stem cell microenvironment 
Stem cell niches are believed to be well-defined environments that are present in almost all 
tissues where the stem cells are anchored and receive multiple regulatory signals to fulfill the 
homeostatic requirements of the tissues they reside in. Contrarily, stem cells are 
conceptually defined by their response to niche signals to self-renew and differentiate in 
order to regenerate specific tissues. This definition pointed stem cells of limited interest when 
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not integrated to this particularly regulating environment (Scadden, 2006). Schofield (1978) 
presented his idea of a specialized environment where stem cells are located and where 
their activity and self-renewal are controlled. He hypothesized that this environment 
promotes differentiation and stem cell maintenance by association with other cell types. This 
scenario also assures the presence of progeny as long the cell is in contact with this locally 
restricted environment or to a similar ‘stem cell niche’. This idea was proposed in reference 
to hematopoiesis and was based on inconsistent findings that showed that the mouse spleen 
colony-forming cells could not be primary hematopoietic stem cells because these cells 
showed an “age-structure”. This concept is explained as follows. Evolutionarily, the spleen or 
kidney function as hematopoietic organs in lower animals such as fish (Catton, 2012; 
Kobayashi et al., 2016), in mice hematopoiesis only partially occurs in the spleen (Wolber et 
al., 2002), while in humans, the spleen functions as secondary HSC niche (Freedman and 
Saunders, 1981; Dor et al., 2006) only under disease condition (e.g. osteopetrosis) . The 
mammalian hematopoietic niche has been definitively located in the BM of the large hollow 
bones.  
Besides the multiple cell types in the hematopoietic stem cell niche, chemokines like stem 
cell derived factor 1 (SDF-1) and cytokines such as stem cell factor (SCF) are known to play 
a major role in stem cell maintenance and hematopoietic regulation (Mendelson and Frenette 
2014). Additionally, the extracellular matrix (ECM), a dense protein mesh secreted by niche 
cells such as the mesenchymal stromal cells (MSCs), is described to provide a natural 
reservoir for soluble growth factors and environmental, structural, and physical cues (Klein, 
1995). This view represents a significant extension of the Schofield model and highlights the 
complexity of the hematopoietic stem cell microenvironment within the BM (Figure 1-3).  
Figure 1-3: The hematopoietic stem cell microenvironment 
The cartoon details components of the hematopoietic stem cell niche and the cell mechanical features 
that are needed to regulate stem cell function. Hematopoietic stem and progenitor cells (HSPCs; red) 
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reside in the BM niche next to cells like MSCs (yellow), endothelial cells (blue), pericytes (orange), and 
ECM components; cells and the ECM mediate adhesion via cell adhesion molecules (CAMs) or 
integrins (ITG). A feature of HSPCs is their mobilization into the blood stream in response to 
granulocyte-colony stimulating factor (G-CSF) or therapeutic factors like plerixafor (AMD), while 
homing occurs towards an SDF-1 gradient. Thus, HSPCs receive niche signals, including biochemical, 
biomechanical, and structural cues from the ECM scaffold, which result in mechanical and 
morphological adaptations, implicating these cues as biomarkers for stem cell properties, including cell 
division and differentiation.  
 
Within the BM, two distinct HSPCs niches have been proposed: the endosteal niche and the 
vascular niche (Wilson and Trumpp, 2006). The vascular niche comprises endothelial cells 
and pericytes, where the endothelial cells form the sinusoids and arterioles and the pericytes 
stabilize the vascular tubes. HSC and endothelial interaction appear very likely since both 
cell types derive from the hemangioblast, a common embryonic precursor (Huber et al., 
2004). Interestingly, only BM located endothelial cells exhibit HSC interaction and 
maintenance factors such as vascular cell-adhesion molecule 1 (VCAM1) or SDF-1 (Sipkins 
et al., 2005) and can promote clonal HSC ex vivo expansion (Li et al., 2003). It is believed 
that the vascular niche provides an environment conducive for activated HSCs, as sinusoids 
and venules allow HSC passage in and out of circulation. Nevertheless, in vivo imaging 
revealed a subpopulation of dormant HSCs in the sinusoidal endothelial cells, indicating 
homeostasis between the vascular and the endosteal niche in the healthy BM (Kiel et al., 
2005). The endosteal niche is anatomically located in BM cavities of the trabecular regions of 
the bone (Lord et al., 1975). Here, a layer of MSCs and MSC-derived osteoblasts cover the 
bone surface, and interact with dormant HSCs. MSCs and osteoblasts reportedly maintain 
HSC function as well as expansion, as identified by genetic stimulation of osteoblast 
proliferation in vivo (Calvi et al., 2003), and can also facilitate in vitro HSC expansion in co-
cultures (Taichman and Emerson, 1998). These findings point towards a direct correlation 
between increasing osteoblast numbers and primary HSC numbers, suggesting that with 
increasing numbers of osteoblast, there is a proportional increase in niche space.    
Figure 1-3 depicts both niches during BM homeostasis; however, under mobilizing 
conditions, the vascular niche could become more relevant for HSCs as they move between 
the blood and the BM (Wright, 2001). Additionally, it could be hypothesized that HSC 
localization close to the blood stream would permit comprehensive monitoring of the 
individual’s hematopoietic status reflected by the concentration of blood-borne factors. Thus, 
fast proliferating short term HSCs could reside in the vascular niche, quickly mobilize in 
response to hematopoietic alterations (Wilson and Trumpp, 2006). In general, the concept of 
two HSC niches within the BM is still under debate and multiple studies have presented 
evidence supporting the presence of the vascular niche (Kiel et al., 2005; Kobayashi et al., 
2010; Itkin et al., 2016) and the endosteal niche (Zhang et al., 2003; Visnjic, 2004; Nilsson, 
2005). However, the current view is that MSC-derived cells play a central role in both niches 
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(Smith and Calvi, 2013). Therefore, in this thesis, we have analyzed the interaction between 
primary human HSCs and MSC-derived ECM scaffolds. These scaffolds are cell free, 
covalently adhere to glass slides, and indeed model the endosteal niche as glass has a 
bone-like elastic modulus in the range of several GPa (Hutmacher, 2001; Liu et al., 2013). 
Additionally, it is acknowledged that 2D in vitro MSC cultures result in progressively 
osteogenic differentiation (Bruder et al., 1997; Banfi et al., 2002; Wagner et al., 2008; Bara et 
al., 2014). Hence, we will focus on the endosteal bone marrow niche.   
1.1.1 The cellular endosteal bone marrow microenvironment 
The BM comprises of two different types of stem cells mentioned before; namely, the 
hematopoietic stem cells and the mesenchymal stem cells. MSCs are capable of 
differentiating into various mesenchymal tissues including fat, cartilage, and tendon, can form 
marrow cells, and differentiate into bone-forming osteoblasts. Additionally, they can be found 
in several other tissues like neural tissue, heart, skin, liver, and muscle, which suggests that 
they possess enormous plasticity (Friedenstein, 1976; Horwitz et al., 2006; Spees et al., 
2016). HSCs reconstitute all blood components by differentiating along several self-renewing 
multipotent progenitor cell lineages. Two major branches develop from these cells and are 
known as the common lymphoid progenitor (CLP) and the common myeloid progenitor 
(CMP). CLPs give rise to T and B-cells as well as natural killer cells, while erythrocytes, 
platelets, granulocytes, and macrophages derive from CMPs (Bryder et al., 2006; Seita and 
Weissman, 2010; Trumpp et al., 2010). Thus, the endosteal niche comprises MSCs and 
HSCs, as well as their progenies including osteoblasts, CLPs, and CMPs (Figure 1-4).  
However, an additional cell type, known as the osteoclast, is crucial for formation of the bone 
and the regulation of its mass. Osteoclasts anchor to bone-specific ECMs and form 
polarized, ruffled, membrane surfaces. Between this membrane and the bone an acidic 
micro-milieu (pH approx. 4.5) develops that subsequently digests the bone surface. 
Osteoclasts derive from the fusion of macrophages and are, therefore, multinucleated cells. 
In order for this fusion to occur exclusively in the bone-forming areas, proximity of 
macrophages and osteoblasts is required. Osteoclastogenesis is controlled through 
parathyroid hormone (PTH) secreted by the parathyroid glands that regulate the blood 
calcium concentration. Osteoblasts express and present a receptor for PTH, which, after 
activation, induces the production of secreted osteoclastogenesis factors including the 
macrophage colony-stimulating factor. These factors then interact with receptors on 
macrophages and induce commitment towards the osteoclast phenotype (Teitelbaum, 2000). 
Therefore, these cells are said to derive, in a broader sense, from HSCs, by a direct interplay 
between osteoblasts and macrophages. 
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1.1.1.1 Mesenchymal stem/stromal cells 
MSCs represent one of two stem cell fractions in the BM (Prockop, 1997). Almost all non-
hematopoietic cells like fibroblasts, osteoblasts, adipocytes, etc. derive from MSCs 
(Cordeiro-Spinetti et al., 2015); however, whether all BM stromal cells represent biologically 
active stem cells for mesenchymal tissue regeneration is still under debate (Horwitz et al., 
2006). Therefore, the International Society for Cellular Therapies (ISCT) has termed these 
cells mesenchymal stromal cells, which allows their continued identification as MSCs 
(Horwitz et al., 2005). Additionally, for reproducible identification of MSCs, the ISCT has 
proposed minimal criteria for defining multipotent mesenchymal stromal cells. When 
maintained in standard culture conditions, MSCs must be plastic-adherent in standard tissue 
culture, must express CD105, CD73, and CD90, and lack expression of CD45, CD34, CD14 
or CD11b, CD79α or CD19, and HLA-DR. Furthermore, MSCs must be able to differentiate 
into osteoblasts, adipocytes, and chondroblasts, under appropriate stimuli (Dominici et al., 
2006).  
When Friedenstein et al. (1968) described MSCs for the first time, they found these cells to 
be a clonogenic subpopulation of BM MNCs and referred them to as colony forming unit 
fibroblasts (CFU-F). MSCs can be isolated from various tissues and the BM is commonly 
used as the source for clinical and research purposes (Horwitz et al., 2006). However, only 
0.001 – 0.01% of BM mononucleated cells (MNC) are MSCs (Boeker et al., 2008). In order to 
isolate MSCs MNCs are cultured, the adherent spindle-shaped fraction is passaged to 
remove contaminating hematopoietic cells and subsequently collected; this process is 
termed “adherent selection” (Colter et al., 2000; Jiang et al., 2002). Beside these minimal 
criteria, multiple surface molecules have been proposed to identify, characterize, and localize 
MSCs, both within the BM and other tissues (Lv et al., 2014).  
Interestingly, MSCs were identified as the most potent cells to regulate HSPC function by 
cell-cell interaction via N-cadherin, very late antigen 4 (VLA4), or cell adhesion molecules 
(CAMs) (Bianco et al., 2008). They secrete large amounts of ECM molecules including 
fibronectins (FN) and collagens that act as scaffolds for cell adhesion and migration. 
Furthermore, these molecules can provide physical and structural constraints that regulate 
HSPC function. Additionally, MSCs and osteoblasts secrete HSPC-regulating cytokines and 
chemokines (Taichman and Emerson, 1998), including SDF-1, Wint-ligands, SCF, bone 
morphogenic protein (BMP), and Notch-ligands. This close interaction of HSPCs and MSCs 
is reminiscent of synaptic interactions and was accordingly termed by Wilson and Trumpp 
(2006) as the “niche-stem-cell-synapse”. 
These observations pointed to the possibility of using MSCs as a feeder layer for HSPC co-
culture (Dexter et al., 1977a) and led, very early on, to the development of immortalized cell 
lines (Roecklein and Torok-Storb, 1995). In 2008, Boeker et al. introduced the human BM-
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derived MSC cell line, single cell picked clone 1 (SCP-1), in which  expression of the human 
telomerase reverse transcriptase (hTERT) abolished telomere shortening and the 
senescence-associated phenotype that led to unlimited proliferation of these MSCs. 
However, SCP-1 cells did not undergo neoplastic transformation. Furthermore, classical 
MSC functions, including multi-lineage differentiation capacity and HSPC support, were not 
altered. Additionally, SCP-1 cells were found to secret considerable levels of SDF-1 
(Arabanian et al., 2014) and ECM proteins (Kräter et al., 2017).   
1.1.1.2 Hematopoietic stem and progenitor cells 
Hematopoietic stem cells represent the second stem cell population located in the BM 
microenvironment (Arroyo et al., 1999; Mitjavila-Garcia et al., 2002; Boisset et al., 2013). 
These cells are defined by their self-renewing capacity and their ability to give rise to all 
mature blood cells (Osawa et al., 1996; Notta et al., 2011). Figure 1-4 illustrates the 
developmental hierarchy of human and mouse HSPCs as most knowledge was gained in 
mice, including the first descriptions of hematopoietic colony formation in the mouse spleen 
after marrow transplantation (Till and McCulloch, 1961; Becker et al., 1963). These initial 
findings identified HSPCs as clonogenic cells with extramedullary niches beside the BM with 
the capacity to find and home to their niches after transplantation (Seita and Weissman, 
2010). They also represent the first tissue-specific stem cells that could be isolated 
(Spangrude et al., 1988) and their discovery led to the fundamental development of 
experimental systems for stem cell expansion, lineage potential evaluation, and fluorescence 
activated cell sorting (Coulombel, 2004; Bryder et al., 2006).    
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Figure 1-4: Hematopoietic development (Bryder et al., 2006) 
In this model of the hematopoietic development hierarchy, self-renewing HSCs are located at the top 
and give rise to common progenitors (CLP and CMP) via multipotent progenitors that show loss of side 
population activity (measured by efflux of Hoechst 33342) during maturation. Additionally, the 
proliferative capacity of the cells increases to the level of progenitors, including the 
granulocyte/macrophage progenitors (GMP) and the megakaryocyte/erythrocyte progenitors (MEP), 
which derive from CMP in order to increase the number of repopulating units. GMPs and MEPs further 
differentiate into erythrocytes, platelets, granulocytes, and macrophages. CLPs give rise to T cells, B 
cells, and NK cells. CMPs and CLPs also give rise to dendritic cells. These cell populations can be 
classified by surface marker expression, as presented for both mouse and human cells. 
 
In translational medicine, HSPCs are the only stem cell source available for routine clinical 
application; e.g., the current standard therapy for multiple hematopoietic disorders is 
autologous stem cell transplantation (Mendelson and Frenette, 2014). As shown in Figure 
1-4 the cell surface marker expression profile is used to identify various stem and progenitor 
cell populations of the hematopoietic system. Early HSPCs are defined as negative for 
lineage (Lin) markers, CD34+, CD90+, and CD38-. However, many other markers like CD133 
have been described to identify subsets of highly potent HSPCs (Yin et al., 1997). Moreover, 
several surface-expressed integrins (ITG) could be used to identify HSPCs as they confer 
stem cell properties via adhesion signaling. ITGβ1 and β2 were shown to promote HSPC 
anchoring to the BM stroma (Teixido et al., 1992). ITGα2 was found to promote HSPC 
maintenance (Boisset et al., 2013). ITGβ3 was found to correlate with properties of quiescent 
HSC (Umemoto et al., 2006) and was required for BM homing (Umemoto et al., 2012). 
Additionally, ITGβ3 can be used to enrich long-term repopulating HSPCs (Umemoto et al., 
2008). Therefore, it is still difficult to distinguish between HSCs and early progenitors by 
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surface molecule expression alone. Nevertheless, HSPCs can be isolated from 3 major 
sources, umbilical cord blood, bone marrow, and peripheral blood (PB) (Cheuk, 2013) and 
can be enriched by sorting based on the surface antigen CD34 before clinical or tissue 
engineering applications (Gordon, 2008). Mobilization of stem cells into the peripheral blood 
is facilitated by the administration of cytokines like granulocyte colony stimulating factor (G-
CSF). Additionally, combined administration strategies that use G-CSF and plerixafor 
(AMD3100), a C-X-C-motive chemokine receptor 4 (CXCR4) antagonist, increase 
mobilization efficiency (Cashen et al., 2007; Giralt et al., 2014). HSPCs express CXCR4, 
which is the receptor for SDF-1. SDF-1 is produced by BM-MSCs and BM-endothelial cells, 
and serves as a gradient for HSPC homing to the BM. It has been shown that HSPCs 
actively migrate towards this gradient, both in vivo and in vitro (Aiuti et al., 1997). As these 
cells are few in number from most graft sources and the number of usable cells is limited, ex 
vivo expansion-cultures have been established using cytokine cocktails like SCF, interleukin 
3 (IL-3) and fms-related tyrosine kinase 3 (FLT-3) (Dexter et al., 1977b; Delaney et al., 2010; 
Csaszar et al., 2012) or small molecules like prostaglandin E2 (North et al., 2007). However, 
in vitro suspension culture of HSPCs leads to heterogeneous cell populations with undefined 
cellular identities (Blank et al., 2008). These findings indicate that a more complex cultivation 
method remodeling the naïve stem cell environment could increase stem cell number and be 
used to understand HSPC regulation ex vivo. 
1.1.2 Extracellular bone marrow microenvironment 
Besides the cellular environment present in the BM niche, extracellular components like ECM 
proteins, morphogens, cytokines, and chemokines are also key regulators of HSPCs. The 
ECM plays a major role in generating and modulating these exogenous factors by presenting 
appropriate adhesion sides, physical and structural cues, and facilitating the storage and 
release of signaling molecules like growth factors (Hynes 2014). Therefore, tissue-
engineering approaches focused on the ECM to develop artificial niches for HSPCs. 
However, naïve reconstitution of in vitro systems, including maintenance of structural and 
functional properties, is rarely achieved due to its inherent complexity (Rosso et al., 2004), as 
described in the following sections.       
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1.1.2.1 Extracellular matrix 
The ECM within the BM niche is a macromolecular structure consisting of multiple proteins 
including fibronectins, collagens, proteoglycans, laminins, and others. Its fibrillar structure is 
insoluble, highly crosslinked, and provides adhesion and guidance structures for cell 
migration. Additionally, its elastic properties can regulate HSPC expansion and MSC 
differentiation (Coulombe et al., 1988; Seib et al., 2009a). Thereby, the ECM is secreted by 
cells residing in the tissue; mostly MSCs in the BM. All cells remain in contact with the ECM, 
and this results in tissue-specific ECM composition (Gattazzo et al., 2014). Figure 1-5 
represents the major components and the integrin-mediated cell-ECM interactions.  
Figure 1-5: ECM components and cell interactions (Karp, 2008) 
The macromolecular structure of the ECM is mainly assembled by major protein components like 
collagens, fibronectins, laminins, and proteoglycans. Cells interact with these structures through 
integrin-mediated adhesions.  
  
Owing to its tissue-specific composition, the ECM guides intercellular interactions and cell-
matrix communication, and thereby acts as a major determinant of cell proliferation and 
differentiation during tissue homeostasis. Nevertheless, besides provision of structural 
stability the ECM is biodegradable and this degradation is mediated by cell-secreted 
proteinases, which then permits cell migration. Proteolytic degradation of the ECM is highly 
conserved between invertebrates and vertebrates and has been shown to be a key process 
in development, tissue homeostasis, and disease progression (Daley et al., 2008; Brown, 
2011; Lu et al., 2011). However, due to the functional diversity of ECM proteins, various 
molecular interactions, and synergistic effects (Figure 1-6), a functional classification of 
single ECM components is almost impossible. Nevertheless, several proteins are known to 
mediate cellular adhesion and cell function regulation and these will be discussed in the 
following sections.  
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Chemokines and Cytokines  
Apart from structural integrity, the BM ECM stores multiple chemokines and cytokines via 
ECM protein binding (Zhang and Lodish in 2008;  
Figure 1-6). Therefore, the ECM is involved in the regulation of HSPC activity by furnishing 
local chemokine/growth factor availability and by establishing appropriate biochemical 
gradients (Hynes, 2012).    
 
Figure 1-6: Domain structures of several ECM proteins (Hynes, 2012) 
Representative ECM proteins show highly complex domain structures and binding sites for multiple 
other ECM proteins and growth factors resulting in a highly crosslinked, complex, 3-dimensional 
scaffold. (A) Fibronectin binds to various growth factors, e.g. hepatocyte growth factor (HGF) and 
vascular endothelial growth factor (VEGF), common ECM proteins such as collagen and fibrillin, and 
presents an RGD-motive (asterisk) for cell-matrix interaction. (B) Fibrillin-1 exhibits high crosslinking 
capability with fibronectin and fibulins, and consists of multiple epidermal growth factor (EGF) binding 
repeats. (C) Latent TGF-β binding protein-1 (TGBP-1) presents TGF-β binding sides, and interacts 
with fibrillin and fibronectin.   
     
Known ECM-associated growth factors are SDF-1, hepatocyte growth factor (HGF), 
fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), interleukin-8 (IL-8), and 
VEGF. FGF and VEGF can bind to heparin and heparan sulfate components of the 
proteoglycans. These sulfates are described to be cytokine reservoirs, and cytokine release 
is mediated by proteolytic ECM degradation. Additionally, FGF receptor binding depends on 
co-binding of heparan chains (Mohammadi et al., 2005) and is identical for TGF-β signaling 
(Shi and Massagué, 2003). During HSC-niche development, orchestrated signaling of bone 
morphogenic protein (BMP) by its native antagonist FGF in the subaortic mesenchyme was 
shown to restrict HSC specification (Pouget et al., 2014). Both cytokines are usually secreted 
by MSCs and anchored to the ECM proteins, implying specific localization within the ECM to 
regulate cellular function.    
A major chemoattractant stored within the BM-specific ECM is SDF1, whose function 
includes lymphocyte homing, mature blood cell activation, and stem cell growth inhibition 
(Whetton and Spooncert, 1998). MSC and osteoblast-derived SDF-1 is anchored on ECM 
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molecules to form a SDF-1 gradient from the endosteal niche to the blood vessels, as 
presented in Figure 1-3 (Jung et al., 2008; Greenbaum et al., 2013; Thon, 2014). SDF-1 
knock out mice display an embryonic lethal phenotype due to lack of migration of HSPCs 
from the fetal liver to the BM  (Nagasawa et al., 1996). It was shown that addition of SDF-1 to 
in vitro HSPC cultures on ECM components like FN increases random cell migration (Lee-
Thedieck et al., 2012) and survival of progenitor cells (Broxmeyer et al., 2003).  
There is emerging evidence on crosstalk and synergistic signaling between growth factors 
and integrins. Rahman et al. (2005) reported the presence of HGF binding domains on FN 
and vitronectin, which coordinate HGF receptor signaling and Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K)-mediated enhanced migration. This indicates induction of 
integrin signaling via HGF receptor; vice versa, cellular adhesion to ECM structures via 
integrins might enhance growth factor signaling.  
Cell adhesion to ECM  
Multiple receptors such as P- and E-selectins, VE-cadherins, and integrins were found to 
mediate HSPC adhesion to endothelial cells, MSCs, and the corresponding ECM. These 
findings correlate with HSPC homing and retention in the bone marrow (Sahin and 
Buitenhuis, 2012). Essentially, integrins (ITGs) are the most important mediators of the cell-
ECM crosstalk. These glycoproteins form heterodimeric transmembrane receptors consisting 
of 18 α-subunits and 8 β-subunits. Each β subunit is bound to a specific α integrin subset, 
thereby resulting in 24 different combinations that are expressed on almost all cell types with 
a specific expression pattern (Hynes, 2002). Integrins were found to sense and transduce the 
bio-chemical nature of the environment into the cell. Moreover, physical cues generated by 
external and internal forces were transduced via ITGs. Therefore, cells can sense 
mechanical properties, the nanostructure and shear forces in the surrounding environment 
(Geiger et al., 2009). An overview of this signaling is presented and described in Figure 1-7. 
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Figure 1-7: Mechanosensing in HSPCs (adapted from Lee-Thedieck and Spatz, 2014) 
This schema illustrates integrin-mediated signaling in HSPCs. ITG subunits heterodimerize after ligand 
recognition and recruit several proteins, including focal adhesion kinase (FAK), paxillin, and vinculin to 
the inner cell membrane. These complexes can either interact with the acto-myosin cytoskeleton to 
adapt cell shape and promote migration via vinculin, or mediate kinase signaling via paxillin and FAK 
phosphorylation. Moreover, crosstalk between the acto-myosin pathway and the kinase pathway was 
demonstrated by cell division control protein 42 homolog (Cdc42) signaling. Cytoskeletal 
rearrangement, through ITG signaling, remodel cell shape, which promotes mechanical signal 
transduction into the nucleus and results in regulation of cellular transcription.  
 
In addition to cytokines, HSPC phenotype can be maintained by cell-matrix adhesions viaat 
adhesion receptors such as integrins. Ex vivo co-cultures of HSPCs and BM niche cells like 
MSCs were used to mimic these interactions, whichhas proven to be a promising tool for 
stem cell expansion (Freund et al., 2006a; Jang et al., 2006; Jing et al., 2010; de Lima et al., 
2012). However, in co-cultures it is nearly impossible to distinguish between cell-cell 
mediated and cell-ECM mediated signaling. ECM components coated on plastic culture 
dishes showed that biomechanical forces of the surrounding environment were transduced to 
cells via integrin signaling (Ross et al., 2013), and that these forces controlled HSPC fate in 
vitro (Engler et al., 2006; Holst et al., 2010; Naba et al., 2014). Thus, these physical aspects 
were shown to be markers for differentiation (Yu et al., 2010) that also drive cell fate 
decisions (Lautenschlaeger et al., 2009; Ekpenyong et al., 2012).  
Following this line, it was found that HSPCs favor anchorage to stiff substrates and exhibit 
random migration as demonstrated by hydrogel scaffolds with different mechanical 
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properties. Generally, gels with an elastic modulus greater than 38 kPa represent hard 
surfaces while those with less than 20 kPa represent soft surfaces (Lee-Thedieck et al., 
2012). The authors demonstrated that ITGα5, ITGβ1, and ITGαVβ3 were responsible for 
HSPC adhesion to fibronectin coatings on hydrogels, and this was inhibited by the addition of 
linear RGD motives. Further, they found that adhesion and migration were inhibited by 
blocking PI3K activity. These findings support the fact of ITG mediated ECM component 
recognition. Transduction of mechanical signals via the acto-myosin cytoskeleton and 
signaling via kinases recruited to ITGs is shown in Figure 1-7. These cross interacting 
pathways lead to morphological and mechanical adaptations in cell shape and increased 
migration (Lee-Thedieck et al., 2012; Lee-Thedieck and Spatz, 2014). Whether adhesion to 
stiff or soft substrates regulates proliferation and differentiation, and thereby functional 
properties described by Holst et al. (2010), is an interesting question in this context. 
Additionally, the transduction of environmental mechanical properties into cell mechanical 
properties via ITG and focal adhesion kinase (FAK) signaling, as demonstrated by Bae et al. 
(2014) in mouse embryonic fibroblasts, would uncover the nature of cellular alignment to 
substrate physical cues, and help establish HSPC mechanical properties as functional 
marker, both in vivo and in vitro.   
As described above, multiple ITGs in destingt expression patterns are found on HSPCs, and 
their suitablitiy as HSPC markers  was analyzed (Potocnik et al., 2000; Carstanjen et al., 
2005; Qian et al., 2006). However, ITGs are not exclusively expressed on HSPCs, but are 
also present on mature blood cells. Umemoto et al. (2012) described ITGαVβ3 signaling as a 
regulator for thrombopoietin-mediated HSPC maintenance. ITGαII2b was found to play a role 
in the maintenance of HSC activity in the mouse embryonic aorta (Boisset et al., 2013) and 
ITGβ3, was found to enrich long term repopulating HSPCs (Umemoto et al., 2008). On the 
other hand, ITGβ3 expression correlates with megakaryocyte–erythroid progenitor cell 
differentiation and is strongly expressed on platelets. Thus, suitable models are required to 
identify stem cell interaction with pure BM-derived ECMs to uncover ITG signaling in the 
context of HSPC regulation. 
Taken together, the ECM provides multiple signals to the HSPCs as illustrated in Figure 1-8. 
These signals control cell fate decisions and proliferation, and mediate tissue homeostasis, 
highlighting the need to decipher and understand cell-ECM interaction in detail to develop 
successful tissue engineering approaches with improved clinical cell replacement therapies. 
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Figure 1-8: ECM mediated cell regulation (Gattazzo et al., 2014) 
The ECM is a direct target of cellular receptors that transduce biomechanical forces into the cell via 
actin fibers, anchors the cell to its environment, and provides tissue stability. The ECM stores and 
presents growth factors to the cell and can be remodeled by cell-derived enzymes. These features 
result in intracellular signaling followed by cellular adaptation.      
 
1.2 Native ex vivo ECM scaffolds  
As described above, the ECM represents a versatile, stability providing compartment with 
tissue-specific properties and cell-regulatory functions (Roskelley et al., 1994). As an 
example, it was shown ex vivo that BM-ECM promotes osteogenic lineage differentiation of 
adipose derived stromal cells; a scenario that is hardly possible in classic tissue culture using 
cytokines (Zhang et al., 2015). Interestingly, these findings also indicate that tissue-specific 
signaling is conserved even in ex vivo experiments. Multiple studies have demonstrated 
functional preservation and organ-specific constitution of ECMs after decellularization of 
whole tissue samples or organs (Gilbert et al., 2006). Additionally, it was shown that 
decellularized ECMs have the potential to induce cellular phenotypes (Furuyama and 
Mochitate, 2000) and prevent ex vivo embryonic stem cell differentiation (Klimanskaya et al., 
2005).  
However, the generation of tissue-like ECMs represents a major challenge with respect to 
the BM environment due to its low density and smooth properties. Prewitz et al. (2013) 
introduced a novel technique to generate decellularized ECMs derived from human BM 
MSCs. The approach uses standard microscopy glass slides as culture carriers. Slides were 
oxidized, aminosilanized, and spin coated with a 0.16% (w/v) poly(octadecen-alt-maleic 
anhydrate) in tetra hydro furan solution, as shown in Figure 1-9. These thin films of 
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covalently bound copolymers were then activated by a tempering for 2 h at 120°C to 
covalently link fibronectin. For ECM production, primary MSCs were cultured on these 
modified glass slides, secreted ECM proteins linked to covalently bound fibronectin to 
prevent detachment from the culture carrier during decellularization. The resulting ECMs 
were used as culture scaffold. This technique did not alter naïve protein cross-linking, as 
demonstrated by formalin-fixed approaches (Beacham et al., 2007) and matrices were 
characterized biochemically, biophysically, and functionally as tissue-mimetic culture 
substrates (Figure 1-9; Seib et al., 2009b; Prewitz et al., 2013, 2015).  
 
 
Figure 1-9: Surface preparation for cell derived ECM scaffolds (Prewitz et al., 2013) 
Freshly oxidized glass slides were coated with 3-Aminopropyl-dimethyl-silyl (aminosilan) and 
fibronectin-functionalized poly(octadecen-alt-maleic anhydrate) (POMA) to generate a covalent link 
between the glass surface and fibronectin. MSCs were cultured on these modified glass slides, and 
after 10 days, secreted ECM remained immobilized to the glass surface, even  during decellulariation. 
  
It has been reported that matrices derived from primary human MSCs possess 
homogeneous topography with a thickness of approximately 1 µm and a stiffness of 
approximately 0.1 kPa, measured by atomic force microscopy (Prewitz et al., 2013, 2015), 
which represents BM bio-mechanical properties (Jansen et al., 2015). Moreover, proteomic 
analyses identified over 500 proteins within the ECM structures with over 50% of these 
annotated as ECM proteins and ECM structural constituents by gene ontology. Additionally, 
anchorage and continued release of BM-related cytokines, including HGF (Takai et al., 
1997), FGF (Choi et al., 2008), IL-8 (Rougier et al., 1998), and VEGF (Asahara et al., 1999) 
were detected. These observations suggest, a native molecular signature of MSC-derived 
ECMs, which served as a naïve reconstituted environment for MSCs (Seib et al., 2009a) and 
HSPCs, and supported both stem cell expansion with the capacity of in vivo repopulation of 
immunodeficient NSG mice (Prewitz et al., 2013). 
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We used this technique to model the HSPC niche ex vivo and analyze the HSPC-ECM 
interaction with respect to contact-mediating structures. However, as it was shown that ECM 
molecules secreted by primary MSCs are highly versatile (Amable et al., 2014) and donor 
dependent (Kalinina et al., 2015), therefore, the use of a reproducible model system such as 
SCP-1 cells to generate consistent ECM scaffolds is recommended.   
 Targeted modulation of ECM components 
To identify key components of the extracellular HSPC niche, genetic modification of the SCP-
1 cell secretome can help investigate the role of individual ECM proteins in HSPC 
maintenance or expansion. Lentiviral vectors can be used to achieve stable expression of 
shRNAs in SCP-1 cells. We adapted a protocol published by Stopp et al. (2013) to effectively 
transduce SCP-1 cells with shRNAs to induce RNA interference, and consequently, a known-
down of a protein of interest. Adequate candidates were identified based on a mass 
spectrometry screen of the MSC secretome (Prewitz et al., 2013) and on functional 
relevance for HSPCs described in literature. A promising candidate was fibulin-1.   
The extracellular matrix protein fibulin-1 was found to negatively regulate HSPC proliferation 
and differentiation. MSCs and osteoblasts strongly express fibulin-1, which keeps HSPCs in 
a quiescent state and maintains their stem cell character (Hergeth et al., 2008). Moreover, 
fibulin-1 is known to interfere with cell migration in the ECM of the endosteal HSPC niche 
(Kluge et al., 1990; Hergeth et al., 2008). The fibulin protein family consists of seven 
members, Fibulin-1 to -7. In humans, four alternative splicing variants of fibulin-1 exist: 
Fibulin-1A, B, C, and D. Compared to variants C and D, variants A and B are expressed at 
lower levels. Splicing variant D was found to co-localize with fibronectin and to inhibit cell 
adhesion by inducing the exposure of anti-adhesive sites on fibronectin (Twal et al., 2015). 
The N-terminal domain-I consists of anaphylatoxin domains, followed by domain-II composed 
of EGF-like modules with high calcium-binding capacity (de Vega et al., 2009). Calcium 
complexation is thought to be important for maintaining HSCs within the niche (Adams et al., 
2006). The fibulin-1 knockout has a perinatal lethal phenotype, demonstrating a crucial role 
for this protein in development (Kostka et al., 2001).  
Aim of the study 
 
19 
2 Aim of the study 
Regenerative medicine is an increasingly interdisciplinary field that strives to combine 
knowledge from biology, physics, chemistry, engineering, and medicine. It aims at developing 
novel cellular therapies that can restore or regenerate normal tissue and organs and their 
functions in response to tissue degeneration or malignant diseases. Classical reconstruction 
attempts include stem cell transplantation. However, several complications such as graft-
rejection or donor site morbidity need to be overcome. In this context, the unique properties of 
stem cells to differentiate towards multiple tissue lineages and cell types offer great potential and 
become highly interesting. For the treatment of malignant blood disorders like lymphoma or 
leukemia, hematopoietic stem cell transplantation has become standard therapy. Hematopoietic 
stem cells are defined by their self-renewing capacity and their ability to give rise to all mature 
blood cells (Osawa M, Hanada KI, Hamada H and H, 1996; Notta et al., 2011). They reside in a 
specialized microenvironment in the BM called the hematopoietic stem cell niche (Arroyo et al., 
1999; Mitjavila-Garcia et al., 2002; Boisset et al., 2013). This niche coordinates differentiation 
and self-renewal, i.e., division without differentiation. However, a major drawback is their low 
numbers and, therefore, the availability of healthy stem cells. Only one in around 10,000 BM 
cells is a hematopoietic stem cell with the ability to support long term hematopoiesis after 
transplantation. To collect HSPCs, BM aspiration or G-CSF stimulated proliferation and 
mobilization into the peripheral blood are common techniques. Nevertheless, to achieve 
therapeutically relevant amounts, in vitro expansion of HSPCs has become a major 
interdisciplinary goal in translational medicine. However, the effective translation of knowledge 
gained on cell communication and regulation within the BM niche that is suitable to culture 
techniques for HSPCs is still unavailable. 
Therefore, the overall goal of this study was to improve the naïve in vitro culture systems based 
on decellularized ECM scaffolds, as described by Prewitz et al. 2013, for HSPC maintenance 
and to identify the functional regulators of the HSPC-ECM interaction. Thus, four major aims 
were defined and addressed in this thesis: 
 For classical in vitro expansion, CD34+ HSPCs isolated from G-CSF mobilized peripheral 
blood suspension cultures were used. Nevertheless, in the BM, cells are connected to 
each other via a complex network of extracellular matrix components. Prewitz et al. 
(2013) described  primary human MSC-secreted ECMs as BM naïve culture substrates. 
As these ECMs undergo alterations due to MSC donor variations and cell senescence, 
we aimed at using SCP-1 cell line to gain highly reproducible ECM scaffolds. SCP-1 is a 
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primary human MSC-derived cell line that was shown to possess all major features of 
MSCs, including surface marker expression and differentiation capacity (Boeker et al., 
2008). Thus, the ECM scaffolds derived from SCP-1 cells should be tested to verify if 
they serve as support structures and natural microenvironments for HSPC expansion.  
  
 The extracellular matrix in the BM stores and presents multiple growth factors and 
cytokines. It also provides physical cues and adhesion sides that may serve as 
migration-guiding structures. Cell-matrix interactions between HSPCs and BM-mimetic 
ECM scaffolds can remodel cell shape and physical properties, which are both major 
regulators of HSPC function. These morphological and biophysical parameters of the 
ECM cultured HSPCs should be described and compared to suspension cultured HSPCs 
and HSPC-SCP-1 co-cultures.  
 
 The CXCR4/SDF-1 axis is known to mediate BM homing and retention of HSPCs 
through a bioactive SDF-1 chemokine gradient produced mainly by MSCs. However, it is 
known that adhesion of HSPCs to stromal extracellular components is achieved primarily 
by integrin-mediated focal adhesions. Therefore, ECM scaffolds derived from SCP-1 
cells were analyzed for SDF-1 incorporation and bio-active presentation. Moreover, 
mediators of the HSPC-ECM interaction via adhesion receptors and formation of 
signaling focal contacts should be identified.  
 
 In the BM, the osteoblast-derived ECM is mainly present in the endosteal hematopoietic 
stem cell niche, and SCP-1 cells can undergo osteogenic differentiation using 
appropriate stimuli. We aimed at identifying the influence of osteogenic induced ECMs on 
HSPC proliferation and adhesion. Additionally, SCP-1 cells are known to be susceptible 
to lentiviral shRNA transduction, which could be used for targeted modulation of ECM 
components by knocking down proteins of interest. We, therefore, aimed to increase 
HSPC adhesion by down regulating fibulin-1, an ECM protein known to form anti-
adhesive sides on fibronectin. The lentiviral shRNA knock down should be established in 
SCP-1 cells, and the adhesion and proliferation of HSPCs on knock down ECMs should 
be analyzed.  
The observations and conclusions from the study can help increase our understanding of HSPC 
regulation when cells adhere to the BM niche and lead to a tunable in vitro expansion system for 
long term repopulating HSPC with homing and effective BM lodgement.    
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3 Materials and methods 
 Materials 3.1
Table 3-1: Materials 
Material Company 
25 gauge needle BD microlance, USA 
30 - 50 gauge needle Braun, Germany 
6-well plates Greiner-Bio One, Austria 
12-well plates  Greiner-Bio One, Austria 
24-well plates  Corning, USA 
BD FalconTM tubes BD Biosciences, USA 
Blunt end filling needle BD Biosciences, USA 
ChemoTx disposable chemotaxis system NeuroProbe, USA 
Cell culture plate (6 well) Greiner-Bio One, Austria 
Cell culture plate (12 well) Greiner-Bio One, Austria 
Cell culture flask (T25) Greiner-Bio One, Austria 
Cell culture flask (T75) Greiner-Bio One, Austria 
Cell culture flask (T175) Greiner-Bio One, Austria 
ECM glass coverslips (6 - 32 mm) Thermo Fischer Scientific, Menzel-Gläser, USA 
FACS tubes VWR, USA 
LS columns Milteniy Biotec, Germany 
Luer-Lock syringes 1 ml – 5 ml BD Biosciences, USA 
Microscopy glass coverslips Greiner-Bio One, Austria 
Microscopy slides Thermo Fischer Scientific, USA 
Microfluidic chips – FLIC20 Zellmechanik Dresden 
Nunc Cryo Tubes Sigma-Aldrich, USA 
Parafilm Sigma-Aldrich, USA 
Petri dish (round) Greiner-Bio One, Austria 
Petri dish (square) Thermo Fischer Scientific, USA 
Pre-separations filters Milteniy Biotec, Germany 
Reaction Tubes Eppendorf, Germany 
Stripette 5 ml – 50 ml  Sigma-Aldrich, USA 
Vacuum filter (0.22 µm pore size, 500 ml) Corning, USA 
 
3.1.1 Chemicals and reagents  
Table 3-2: Chemicals and reagents 
Chemical/ Reagent Company 
2-phospho-ascorbic acid Sigma-Aldrich, USA 
3-aminopropyl-triethoxy-silane (amino-silan) ABCR, Germany 
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, USA 
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Acetic acid Merck, Germany 
Acetone  Sigma-Aldrich, USA 
Acrylamide (40%) (w/v) GE Healthcare, UK 
Agarose Sigma-Aldrich, USA 
Alexa Fluor 488 phalloidin Thermo Fischer Scientific, USA 
Alexa Fluor 647 phalloidin  Thermo Fischer Scientific, USA 
Ammonia solution Sigma-Aldrich, USA 
Ammonium persulfate (APS) Carl Roth, Germany 
β-glycerol-phosphate Sigma-Aldrich, USA 
Bisacryamide (2% w/v) GE Healthcare, UK 
Biocoll 1.077 g/ml Merck, Germany 
Blocking solution Santa Cruz Biotechnology, USA 
Bovine Serum Albumin (BSA) Sigma-Aldrich, USA 
Cellcarrier A / B Zellmechanik Dresden, Germany 
Coomassie blue Merck, Germany 
CXC-motiv-chemokin 12 (CXCL12, SDF-1) PeproTech, USA 
Dexamethasone Sigma-Aldrich, USA 
Dimethylsolfoxid (DMSO) Merck, Germany 
ECL plus western blotting detection reagents  Amersham, UK 
Ethanol (absolute) Merck, Germany 
Fetal Calf Serum (FCS)  Biochrom, Germany 
Fibronectin (FN) Roche, Germany 
FMS-like tyrosine kinase 3 ligand (FLT3) human Miltenyi Biotec, Germany 
GeneRuler 100bp DNA ladder Thermo Fischer Scientific, USA 
Granulocyte-colony stimulating factor (G-CSF) Peprotec, USA 
Glycine Carl Roth, Germany 
Human Serum Albumin (HSA) 200g/ ml Baxter, Germany 
Hydrogen peroxide (H2O2) Merck, Germany 
Interleukin 3 (IL-3)  Milteniy Biotec, Germany 
Isopropanol Merck, Germany 
LB medium VWR chemicals, USA 
Methanol Merck, Germany 
Milk powder Carl Roth, Germany 
Milli-Q Water purified and deionized water Millipore, Germany 
Paraformaldehyde (PFA) Sigma-Aldrich, USA 
Polyethylenimine (PEI) Sigma-Aldrich, USA 
Percoll 1.073 g/ml Biochrome, USA 
Phosphate buffered saline (PBS) Thermo Fischer Scientific, Gibco, USA  
ply(octadecene alt maleic anhydride) (POMA)  Polysciences Inc., USA 
Potassium chloride Sigma-Aldrich, USA 
Prestained Protein Ladder PageRuler Thermo Fischer Scientific, USA 
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Propidium Iodide (PI) Thermo Fischer Scientific, Invitrogen, USA 
Puromycin  Sigma-Aldrich, USA 
PVDF membrane GE Healthcare, UK 
RedSafe iNtRON Biotechnology, Korea  
Roti®-Load 2 –buffer Carl Roth, Germany 
SDS Carl Roth, Germany 
Sodium chloride (NaCL) Carl Roth, Germany 
Sodium citrate 4% Fenwalinc, USA 
Sodium Hydroxide (NaOH) Merck, Germany 
Stem Cell Factor (SCF) human Milteniy Biotec, Germany 
Tetrahydrofuran (THF) Sigma-Aldrich, USA 
Tetramethylethylenediamine (TEMED) Carl Roth, Germany 
Tris base Carl Roth, Germany 
Triton X-100 Merck, Germany 
Trypan blue solution Sigma-Aldrich, USA 
Tween20 Carl Roth, Germany 
Trypsin-EDTA Sigma-Aldrich, USA 
 
3.1.2 Kits  
Table 3-3: Kits 
Kit Company 
Bicinchoninic Acid (BCA) protein assay kit Thermo Fischer Scientific, USA 
BrdU Staining Kit for Flow Cytometry APC Affymetrix eBioscience, USA 
CD34 Microbead Kit, human Milteniy Biotec, Germany  
CellTraceTM CFSE Cell Proliferation Kit  Thermo Fischer Scientific, USA 
DreamTaq PCR Master Mix Thermo Fischer Scientific, USA 
DuoSet ELISA Development kit for SDF-1 R&D systems, USA 
M-Per mammalian protein extraction reagent Thermo Fischer Scientific, USA 
Pierce Bicinchoninic Acid (BCA) protein assay kit Thermo Fischer Scientific, USA 
Plasmid Kit with QIAGEN-tip 500 QIAGEN, Netherlands 
ReliaPrep RNA Cell Miniprep System Promega, USA 
RevertAid First Strand cDNA Synthesis kit Thermo Fischer Scientific, USA 
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3.1.3 Media 
Table 3-4: Media 
Medium Company 
CellGro medium CellGenix, Germany 
Dulbecco´s Modified Eagle Medium (DMEM) Thermo Fischer Scientific, Gibco, USA 
HSC CFU complete with Epo Milteniy Biotec, Germany 
Human Stem MACS medium  Milteniy Biotec, Germany 
Iscove's Modified Dulbecco's Media (IMDM) Biochrome, USA 
 
3.1.4 Antibodies  
Table 3-5: FACS antibodies 
Anti-human Clone Company Catalogue No. 
CD11b PE ICRF44 Biolegend, USA 301306 
CD29 PE MAR4 BD Biosciences, USA 555443 
CD34 APC AC136 Milteniy Biotec, Germany 130-090-954 
CD41 FITC MAB4143 Immunotech, France PN IM0649 
CD44 FITC G44-26 BD Biosciences, USA 555478 
CD45 V500 HI30 BD Biosciences, USA 560777 
CD49d APC 9F10 BD Biosciences, USA 559881 
CD49e PE IIA1 BD Biosciences, USA 555617 
CD49f FITC GoH3 BD Biosciences, USA 555735 
CD51 PE NKI-M9 BioLegend, USA 327909 
CD61 PE VI-PL2 BD Biosciences, USA 555754 
CD73 PE AD2 BD Biosciences, USA 550257 
CD90 APC 5E10 Affymetrix eBioscience, USA 17-0909-73 
CD105 FITC SN6 AbD serotec, USA MCA1557F 
CD133/1 PE AC133 Milteniy Biotec, Germany 130-080-801 
CD146 APC 541-10B2 Milteniy Biotec, Germany 130-092-849 
CD166 PE 3A6 BD Biosciences, USA  559263 
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Table 3-6: primary antibodies 
Antibody Clone Company Catalogue No. 
Polyclonal rabbit-anti-
human-CXCL12&/SDF-1 Polyclonal Acris Antibodies, Germany PP1067P1 
Polyclonal rabbit-anti-
human-CXCR4 Polyclonal Abcam, UK ab2090 
Polyclonal rabbit-anti-
human-Fibulin-1 Polyclonal SantaCruz Biotechnology, USA Sc-20818 
Monoclonal mouse- anti-
human-ITGαVβ3 VNR-1 Abcam, UK ab78289 
Polyclonal rabbit-anti-
human-p-paxillin (Tyr118) Polyclonal CellSignaling, USA 2541S 
Monoclonal mouse-anti-
human-vinculin hVIN1 Sigma-Aldrich, USA V9131 
 
Table 3-7: secondary Antibodies 
Antibody Clone Company Catalogue No. 
Polyclonal goat-anti-
mouse-Cy2 Polyclonal Dianova, Germany 115-225-166 
Polyclonal sheep-anti-
rabbit-Cy3 Polyclonal Sigma-Aldrich, USA C2306 
ECl-polyclonal-donky-anti-
rabbit IgG-HRP Polyclonal GE Healthcare, UK NA934-100UL 
 
3.1.5 Primers, sh-RNA sequences, and vectors  
Table 3-8: Primers 
Primer Sequence 5´-3´ Size Accession No. 
Fibulin-1 forward CCT ACC GCT GCA TCA ACA T   
Fibulin-1A reverse ATG CAG AGT TCC CTA CGA TCA 236 NM_006487 
Fibulin-1B reverse CCT TCC CTT CTT GGA TTT CTG 236 NM_006485 
Fibulin-1C reverse GAT TCT CAT GGC AAG GCA AG 246 NM_001996 
Fibulin-1D reverse GAG ATG ACG GTG TGG GAG AT 322 NM_006486 
GAPDH forward GCC AAA AGG GTC ATC ATC TC   
GAPDH reverse GGT GCT AAG CAG TTG GTG GT 198  
 
Table 3-9: sh-RNA sequences 
Clone Target sequence 5´-3´ Clone ID 
pLKO.1 puro shRNA vector 10 CCTCCAAGAAACGGATAAGAT TRCN0000055675 
pLKO.1 puro shRNA vector 11 CGAATGCAAGACGGGTTACTA TRCN0000055676 
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Table 3-10: Vectors 
Vector Reference 
pLKO.1 puro  Mission RNAi (Mission shRNA), Sigma-Aldrich, USA 
psPAX Trono Lab Packaging and Envelop Plasmids (Addgene#12259) 
pVSVg Stewart et al., 2003 
 
3.1.6 Equipment 
Table 3-11: Equipment 
Equipment Company 
ACCellerator Zellmechanik Dresden, Germany 
Autoclave DE-23 Systec Sci, Germany  
Biological Safety Cabinet HeraSafe Thermo Fischer Scientific, USA 
BD FACSAria III BD Biosciences, USA 
BD FACSCalibur BD Biosciences, USA 
BD LSRII BD Biosciences, USA 
Centrifuge Biofuge primoR Thermo Fischer Scientific, Heraeus,USA  
Centrifuge Rotixa 120RS Hettich-Zentrifugen, Germany 
CO2-Incubator Heraeus HERAcell 240 Thermo Fischer Scientific, USA 
G:Box. Syngene, USA 
Heraeus heating and drying oven Thermo Fischer Scientific, USA 
LAS-3000 imager Fujifilm, Japan 
Laser Scanning Microscope, Leica SP5 Leica Microsystems, Germany 
Light microscope Axiovert 200M Carl Zeiss, Germany 
Light and fluorescence microscope Axiovert S100 Carl Zeiss, Germany 
MACS Quant Analyzer Milteniy Biotec, Germany 
Microplate reader Anthos htII Richmond Scientific, UK 
Microwave Continent MW 800 G GGV Exquisit, Germany 
MilliQ Purification System for deionized water Millipore, Germany 
Molecular Imager Gel Doc Bio-Rad Laboratories, USA 
NanoDrop 200 Thermo Fischer Scientific, USA 
Neubauer counting chamber LO Laboroptik, UK 
Page chamber Bio-Rad Laboratories, USA 
Pipetboy Easypet Eppendorf, Gemany 
Pipets 0.1 µl – 5000 ml Eppendorf, Germany 
PowerPac Universal Bio-Rad Laboratories, USA 
Quadro MACS Seperator Milteniy Biotec, Germany 
Spincoater RC5 Süss Microtec, Germany 
Vacuubrand-CVC2000 Brand, Germany 
Vacuum pump VWR, Germany 
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3.1.7 Software  
Table 3-12: Software 
Software License Developer/ Company 
Anaconda (Python) Open Source Continuum Analytics, USA 
Chemotaxis and Migration Tool Proprietary Freeware Ibidi, Germany 
Flowing Software Proprietary Freeware Perttu Terho, Turku Centre for Biotechnology  
FlowJo Software 10.0 TreeStar License TreeStar, USA 
GraphPadPrism 5.0 GraphPadPrism License  GraphPad Software, USA 
ImageJ / Fiji Public Domain Wayne Rasband (retired from NIH) 
Inkscape Open Source Public development  
MS Office Microsoft License Microsoft, USA 
ShapeIn Zellmechanik Dresden License Zellmechanik Dresden, Germany 
ShapeOut Proprietary Freeware Zellmechanik Dresden, Germany 
 
 Methods 3.2
3.2.1 Cell preparation and culture 
 Mesenchymal stromal cells 3.2.1.1
Bone marrow aspirates were collected from healthy donors at the Bone Marrow Transplantation 
Center of the University Hospital, TU Dresden, after obtaining verbal and written consent. The 
study was approved by the local ethics committee (ethical approval no. EK221102004, 
EK47022007). Briefly, bone marrow aspirates were diluted with PBS at a ratio of 1:5. A 20 ml 
aliquot was layered over a 1,073 g/ml Percoll solution and centrifuged at 200 x g for 15 min at 
room temperature (RT) with low acceleration and without deceleration. After centrifugation, 
mononuclear cells at the interphase were recovered and washed with 50 ml PBS. All cells were 
seeded onto a T-75 cell culture flask in low glucose DMEM supplemented with 10% FCS and 
cultured at 37°C, 5% CO2 in a humidified incubator. After two days, hematopoietic and non-
adherent dead cells were removed by washing with PBS. Medium was changed twice a week. 
MSCs were passaged using 0.25% Trypsin-EDTA. Cell viability was determined using the 
Trypan blue dye exclusion method and cell counting in a Neubauer hemocytometer. 
Human MSC preparations from individual donors were not pooled. MSCs used in this study were 
chosen according to the minimal criteria for MSCs, according to the International Society for 
Cellular Therapy (ISCT) guidelines (Dominici et al., 2006) and prior characterization of 
osteogenic differentiation capacity, as measured by alkaline phosphatase-activity (AP-activity, 
Hempel et. al, 2012) at the Institute of Physiological Chemistry, TU Dresden). 
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 Hematopoietic stem cells 3.2.1.2
G-CSF (granulocyte colony-stimulating factor)-mobilized peripheral blood was obtained from 
healthy donors at the Bone Marrow Transplantation Center of the University Hospital, TU 
Dresden, after obtaining verbal and written consent. The study was approved by the local ethics 
committee (ethical approval no. EK221102004, EK47022007). CD34+ HSPCs were purified from 
leukapheresis samples using the human CD34 Microbead Kit. Briefly, a 2 ml aliquot of PB was 
washed in 23 ml washing buffer (50 ml PBS + 15 ml 4% sodium citrate, at 4°C). After 
centrifugation (200 x g, 5 min without deceleration, 4°C), the cell pellet was resuspended in 
300 µl cold separation buffer (50 ml PBS + 15 ml 4% sodium citrate + 5 ml human serum 
albumin) at the rate of 1 x 108 total nucleated cells (TNCs), 100 µl blocking solution added, 
incubated for 5 min at RT, 100 µl CD34 antibody-conjugated magnetic beads added, and 
incubated for 15 min in the refrigerator. To ensure an optimal mixing of the cell suspension, the 
sample was agitated every 5 min, followed by washing in 25 ml separation buffer. After 
centrifugation (200 x g, 5 min without deceleration, 4°C), cells were resuspended in 2 ml 
separation buffer. For cell separation, LS Columns equilibrated with 2 ml separation buffer and 
Pre-Separation Filters (30 µm) were placed in a Quadro MACS Separator. The cell suspension 
was added and flow-through collected in a falcon tube. Bound cells were washed 4 times with 
2 ml separation buffer, the LS column removed from the MACS separator, and the cells plunged 
out using 8 ml separation buffer. Cell were collected by centrifugation (200 x g, 5 min without 
deceleration, 4°C), followed by a second cell separation step to increase purity.  
Purified CD34+ HSPCs were seeded onto 6 well plates containing ECM scaffolds and grown in 
CellGro medium supplemented with 2.5 ng/ml SCF, IL-3, and Flt-3, for 5, 7, or 11 days without 
medium change. As controls, CD34+ HSPCs were seeded onto 6 well plates without ECM 
scaffold slides (plastic culture dish, PCD-cells). For co-culture experiments, SCP-1 cells were 
seeded at a density of 1 x 105 cells per cm² and grown in DMEM supplemented with 10 % FCS 
for 48 h, before the addition of freshly isolated CD34+ cells at 1 x 104 cells per cm². SCP-1/HSPC 
co-cultures were maintained in cytokine supplemented CellGro and were cultured at 37°C, 5% 
CO2 in a humidified incubator. 
 Single cell picked clone 1 (SCP-1) cells 3.2.1.3
To produce uniform and highly reproducible ECM scaffolds, we predominantly used SCP-1 cells. 
This mesenchymal cell line originates from human MSCs overexpressing the human telomerase 
reverse transcriptase to facilitate immortalization. These cells are known to display key features 
of MSCs like CD73, CD90, and CD105 surface marker expression, and osteogenic, adipogenic, 
and chondrogenic differentiation potentials. The SCP-1 cell line was generously provided by 
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Matthias Schieker (Boeker et al., 2008). Cells were cultured in standard medium consisting of 
low-glucose DMEM supplemented with 10% FCS at 37°C and 5% CO2 in a humidified incubator. 
Cells were passaged once a week using Trypsin-EDTA and the medium was changed twice a 
week 
3.2.2 Generation of surface immobilized ECM preparations 
Surface immobilization of ECMs and their subsequent characterization has been described in 
detail by Prewitz et al., 2013. Generation of ECM preparations is described in brief as follows. 
 Surface functionalization  3.2.2.1
Aminosilane chemistry was applied to round glass slide surfaces to allow covalent attachment of 
POMA and bioactive molecules like FN. Coverslips were oxidized in a 1:1:5 ratio of ammonia, 
H2O2 and H2O at 70°C for 15 min, followed by two washing steps in Millipore-water, and a drying 
step using pressurized nitrogen. Surface modification of glass substrates were done by 
incubation in 1,16 ml aminosilan in 250 ml Isopropanol/ H2O (1:9) for 1 h, followed by rinsing in 
isopropanol and drying at 120°C for 1 h. This step also ensures stable bonding of the copolymer 
solution (0.16% POMA in THF;Figure 1-9Fehler! Verweisquelle konnte nicht gefunden 
werden.). Using spin-coating, thin films of POMA were generated and covalently bound to glass 
surfaces. To activate the surface,slides were tempered for 2 h at 120°C and rinsed with acetone 
for 15 min. Slices were stored for up to 3 months, protected from light. 
Using POMA coated glass slides, proteins can be covalently linked to glass surfaces that then 
serve as linkers to cell-derived ECM. After sterilization in an autoclave at 121°C and annealing in 
a hot-air oven at 120°C for 2 h, proteins bind to the anhydride moieties of the copolymer via free 
amino groups. FN was suspended in PBS (50 µg/ml) and incubated on annealed surfaces for 
1 h at 37°C and 5% CO2 in a humidified incubator to a final concentration of 5 µg/cm².   
 ECM preparation 3.2.2.2
To generate ECM scaffolds, SCP-1 cells were seeded at a density of 1 x 104 cells per cm² on 
functionalized glass slides and grown to confluency at 37°C and 5% CO2 in a humidified 
incubator. The medium was changed every second day. To obtain cell-free ECM structures, 
cultures were decellularized at day 7 to 10 using double distilled water supplemented with 
20 mM ammonium hydroxide, and the ECM acquired by gentle agitation for 10-min at room 
temperature. The resulting protein layers were washed thrice with deionized water and twice 
with PBS containing calcium and magnesium. These ECM scaffolds were used directly or stored 
in PBS containing calcium and magnesium for up to 4 weeks at 4°C. 
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3.2.3 Flow cytometry and fluorescent activated cell sorting 
For flow cytometry and FACS sorting, cells needed to be harvested. PCD-cultured and SN-cells 
were harvested after three washes in FACS buffer (PBS + 5% FCS), and AT-cells were 
detached by vigorous pipetting in FACS buffer. SCP-1 cells were detached by incubation with 
Trypsin-EDTA for 5 min, after the cell layer was washed with PBS, and the trypsin-EDTA 
reaction was stopped by adding 5 times greater volume of a medium containing 10% FCS. After 
centrifugation (200 x g, 5 min, RT), cells were stained for surface markers using fluorescent-
labeled antibodies listed in Table 3-5, and corresponding human immunoglobulin G controls 
were used. At least 105 – 106 cells were resuspended in FACS buffer and incubated with 
antibodies in the dark for 20 min RT, according to the manufacture’s protocol. Stained cells were 
washed twice with 5 ml FACS buffer and analyzed directly or fixed using 1% PFA. Cells were 
measured by flow cytometry using the FACScalibur or LSRII and were analyzed by FlowJo 
software (version 10.0, Tree Star). Fluorescent activated cell sorting for HSPCs was performed 
on a FACSAria machine according to the scheme provided in Figure 4-16. Dead cells were 
excluded by 4′,6-Diamidin-2-phenylindol (DAPI) staining, and sorted cells were harvested in ice-
cold PBS. 
3.2.4 Cell cycle analyses 
The BrdU assay for HSPCs was carried out according to manufacturer’s instructions for the 
BrdU Staining Kit for Flow Cytometry using 10 µM BrdU-staining solution. Briefly, BrdU was 
thawed on ice, diluted in PBS under sterile conditions to a working concentration of 1 mM, and 
10 µl of this working solution added directly to 1 ml cell culture medium. Incubation was titrated 
to be most efficient at 2 h. SN-cells were harvested by collecting the cell culture supernatant, 
followed by washing of the ECM with 2 ml FACS buffer. AT-cells were detached by vigorous 
pipetting using 3 x 2 ml FACS buffer. Cells were centrifuged (200 x g, 5 min, RT) and 
resuspended at 1 – 2 x 106 cells in PBS by pulse-vortexing. Freshly prepared 1x BrdU Staining 
Buffer working solution (1 mL) was added, the cell suspension gently mixed, and incubated for 
15 min at RT in the dark. After washing of cells twice with 2 ml FACS buffer, DNA was stained 
with 1 µg/ml propidium iodide for 30 min at RT in the dark. Cells were again washed twice with 
2 ml FACS buffer. DNase I solution was thawed on ice and diluted by adding 700 µl FACS buffer 
to 300 µl DNase I solution. Cells were resuspended in 100 µl DNase I working solution and 
incubated for 1 h at 37°C in the dark. Cells were then washed twice with 2 ml FACS buffer, 
resuspended in 100 µl FACS buffer, 5 µl of anti-BrdU fluorochrome-conjugated antibody added, 
and incubated for 30 min at RT in the dark. Cells were washed twice with 2 ml FACS buffer, 
followed by fluorescence acquisition on a FACSLSRII. 
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3.2.5 Proliferation analyses  
The CellTraceTM CFSE Cell Proliferation Kit was used to detect HSPC generations according to 
manufactures instruction. CellTrace CFSE staining solution was prepared by diluting 1 µl in 
999 µl sterile PBS. Freshly isolated CD34+ cells were centrifuged (200 x g, 5 min, RT), 
supernatant removed, cells resuspended in CellTrace CFSE staining solution at 105 cells per 
100 µl, followed by 20 minutes incubation at 37°C in the dark. 1 ml DMEM + 10% FCS was 
added, followed by incubation for a further 5 min at 37°C in the dark. Cells were centrifuged 
(200 x g, 5 min, RT), resuspended in pre-warmed CellGro medium containing cytokines as 
described in 3.2.1.2, and prepared cells cultured for 5 d either on Matrix or PCD at 37°C and 5% 
CO2 in a humidified incubator. After cells were collected, washed, and counterstained using 
CD34-APC as described in 3.2.3, the number of cell divisions was quantified according to the 
CFSE signal intensity on a LSRII flow cytometer and analyzed on FlowJo-software. 
3.2.6 Colony forming unit cell assay (CFU-GEMM) 
To investigate the clonogenicity of HSPCs, colony-forming unit cell assays were performed in 
semisolid human Stem MACS medium. Briefly, cells were washed, counted, and resuspended at 
a final volume of 1 x 105 cells in 1 ml PBS. Cells (n=500) were suspended in 3 ml human Stem 
MACS medium, 1 mL aliquots were seeded in 3 petri dishes (35x10 mm), and cultivated at 37 °C 
in a humidified 5% CO2 atmosphere. This assay triggers differentiation towards myeloid 
lineages, i.e., granulocytes, erythrocytes, monocytes; and megakaryocytes, is mediated by 
multiple growth factors (Ogawa, 1989) and therefore, yields the number of HSCs and common 
myeloid progenitors (Carow et al., 1993). After 14 days, each well was scored for the number of 
burst-forming units–erythroid (BFU-E), colony forming units–erythrocytes, colony forming units–
granulocyte (CFU-G), CFU–granulocyte macrophage (CFU-GM), and CFU–macrophage (CFU-
M), according to standard criteria (Pereira et al., 2007).  
3.2.7 Migration assays 
 Transwell migration 3.2.7.1
A transwell migration system was used to test HSPC migration towards a gradient of SDF-1, 
before and after ECM culture. This system uses a 96-well plate that is reversibly covered by a 
porous membrane (pore size = 5 μm). The cavities of the provided wellplate were filled with 
30 μl medium containing 100 ng/ml SDF-1. Spontaneous migration rates were examined without 
adding SDF-1. After placing the membrane onto the plate, 60 μl of Cellgro medium containing 
3x104 cells was added onto the membrane, the system placed  in a humidified incubator at 37°C 
with 5% CO2, and cells allowed to migrate for 3 h. Control wells used 30 μl medium containing 
3x104 cells for analyses. The total number of migrated cells was counted by removing the porous 
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membrane and placing the 96-well plate on the MACS Quant Analyzer. Data were analyzed 
using FlowJo software. 
 Live cell migration 3.2.7.2
To analyze the spontaneous cell migratory behavior on ECM preparations, SN-cells were 
removed by washing 3 times with PBS. AT-cells were live-cell imaged for 40 min using an 
inverted microscope Axiovert S100 (Carl-Zeiss). An image was taken every 30 sec and cell 
migration was analyzed using Fiji software and the Chemotaxis and Migration Tool. For 
functional integrin blocking, AT-cells in 6 well plates were pre-incubated for 1 h before migration 
analysis with either 2 µg monoclonal mouse-anti-human-ITGαVβ3 antibody or appropriate IgG1 
control in serum-free CellGro medium. 
3.2.8 Confocal laser scanning microscopy 
PCD cultured, SN- and AT-cells on ECM preparations or SCP-1 cells alone or in co-culture with 
HSPCs were washed once with ice cold PBS. Cells were fixed with 4% paraformaldehyde for F-
actin, CXCR4, and SDF-1 staining or with methanol/acetone (1:1) for integrin, vinculin, and p-
paxillin staining. After a second washing step, cells were permeabilized using PBS containing 
0.1% Triton X-100 (T-PBS) for 15 min, followed by blocking for 1 h with T-PBS containing 10% 
FCS and 1% HSA (IF buffer). Antibody dilutions were prepared in IF buffer as follows: 
monoclonal mouse-anti-human-ITGαVβ3 1:200, polyclonal rabbit-anti-human-CXCR4 1:500, 
polyclonal rabbit-anti-human-CXCL12/SDF-1 1:500, monoclonal mouse-anti-human-vinculin 
1:500, and polyclonal rabbit-anti-human-p-paxillin (Tyr118) 1:50. Alexa Fluor 488 phalloidin for 
actin staining was prepared by dissolving one vial Alexa Fluor 488 phalloidin in 1 ml methanol 
and 5 µl added to 200 µl cell-IF buffer solution. Cells were incubated overnight at 4°C. After 
washing thrice for 10 min with T-PBS, secondary antibodies were incubated for 1 h RT in IF 
buffer as follows: polyclonal sheep-anti-rabbit-Cy3 1:200, or polyclonal goat-anti-mouse-Cy2 
1:200. After washing thrice with T-PBS for 10 min, DNA was counter confocal laser scanning 
microscopy. 
3.2.9 Real-time deformability cytometry (RT-DC) 
RT-DC was performed as described in detail by Mietke et al., 2015; Otto et al. and 2015; Xavier 
et al., 2016. Freshly isolated PB and BM CD34+ cells, SN- and AT-cells from ECM, SCP-1 co-
cultures, and PCD-cultured HSPCs were harvested as described above. Centrifuged cells 
(200 x g, 5 min, RT) were washed with PBS and suspended in PBS containing 0.63% 
methylcellulose (MC-PBS) at a concentration of 1-2 x 106 cells/ml. The cell suspension was 
drawn in a syringe and connected to a microfluidic chip as depicted in Figure 3-1. The chip is 
made from Polydimethylsiloxane (PDMS) and is mounted on a glass slide. The chip consists of a 
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central channel separated by two reservoirs. A second syringe, filled with MC-PBS, was used to 
hydrodynamically focus the cells inside the constriction of the chip (Figure 3-1, middle plane), 
which was then mounted on an inverted microscope. A syringe pump flushes the cells through 
the channel at a constant flow rate of 0.06 µl/sec that results in the cells being deformed into a 
characteristic bullet-like shape. A high-speed CMOS camera images the cells at the end of the 
constriction and cell cross-sectional area (size [µm²]) and deformation are calculated in real-
time.. 
 
Figure 3-1: Real-time deformability cytometry  
Schematic representation of RT-DC setup and measurement. Sample-flow contains cells and sheath-flow 
contains MC-PBS with same viscosity as the sampkle flow. A syringe pump flushes sample-flow and 
sheath-flow through the microfluidic chip at constant speed with a 1:3 ratio of sample- to sheath flow, 
which hydrodynamically focuses the cells in the middle of the channel constriction. Here cells are imaged, 
and the deformation and cell size is calculated in real-time. 
 
Statistical comparison of deformation was carried out using 1-dimensional linear mixed model 
analysis. One fixed and one random effect were considered in order to analyze the difference 
between subsets of cells and to consider replicate variance, respectively. P-values were 
determined by a likelihood ratio test that compared the full model with a model lacking the fixed 
effect term. 
3.2.10 Molecular biological methods 
 RNA isolation, reverse transcription, and PCR 3.2.10.1
For RNA isolation, SCP-1 cells were cultured in T-75 flasks with normal DMEM or osteogenic 
medium (DMEM + 10% FCS with 100 nM dexamethasone, 10 nM β-glycerol-phosphate, and 
50 µM 2-phospho ascorbic acid) until confluence, followed by an additional 10 days of culture. 
RNA isolation was performed according to manufacturer’s protocol for adherent cells using the 
ReliaPrep RNA Cell Miniprep System. Briefly, cells were detached by Trypsin-EDTA treatment 
as described in 3.2.1.1, collected by centrifugation (200 x g, 5 min, RT), cell pellet resuspended 
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in ice cold PBS, and again pelleted by centrifugation. The supernatant was discarded, 106 cells 
resuspended in 250 µl BL+TG (1,500 µl 1-Thioglycerol to 150 ml BL buffer) by vortexing, 85 µl 
Isopropanol added and mixed by vortexing for 5 sec. The lysate was transferred to a Minicolumn 
and centrifuged (12,000 x g, 30 sec, RT) with total RNA trapped in the Minicolumn. RNA Wash 
Solution (500 µl) was added and again centrifuged (12,000 x g, 30 sec, RT). DNase I working 
solution was prepared by mixing 2 µl Yellow Core Buffer, 3 µl MnCl2, and 3 µl DNase I, and 
added to Minicolumn, followed by 30 min incubation at RT. To wash the column, 200 µl Column 
Wash Solution was added and centrifuged (12,000 x g, 15 sec, RT), followed by 500 µl RNA 
Wash Solution and centrifugation (12,000 x g, 30 sec, RT). The second washing step used 
300 µl RNA Wash solution and 2 min centrifugation at maximum speed. RNA was eluted by 
centrifugation (12,000 x g, 1 min, RT) using Nuclease-Free Water. RNA concentration was 
determined on a NanoDrop 200 UV-Vis spectrophotometer and up to 5 µg total RNA was 
reverse transcribed using the RevertAid First Strand cDNA Synthesis kit. Briefly, an appropriate 
amount of RNA was mixed with 1 µl Oligo (dT)18 primer and water to a volume of 12 µl. This 
mixture was incubated for 5 min at 65°C, chilled on ice, and 4 µl 5X Reaction Buffer, 1 µl 
RiboLock RNase Inhibitor (20 U/µl), 2 µl 10 nM dNTP Mix, and 2 µl RevertAid M-MuLV RT 
(200 U/µl) added to make a total volume of 20µl. The suspension was mixed and cDNA reverse 
transcribed by 60 min incubation at 60°C. The reaction was terminated by heating the mixture to 
70°C for 5 min. PCR for fibulin-1 was done using the DreamTaq PCR Master Mix and primers 
were designed according to Hergeth et al., 2013 (Table 3-8). An initial denaturation step 
occurred at 96°C for 1 min, followed by 45 cycles of replication (denaturation at 96°C for 45 s, 
annealing at 57°C for 40 s, elongation at 72°C for 1 min) and was terminated with a final 
elongation at 72°C for 10 min, followed by cooling to 4°C. PCR products were directly analyzed 
in a 1.5% agarose gel stained with RedSafe or stored at -80°C till usage. Agarose gels were 
imaged using Syngene G:Boxsoftware and GAPDH was amplified using primers depicted in 
Table 3-8 as the housekeeping gene. The GeneRuler 100bp DNA ladder was used ot estimate 
product size. 
 Lentiviral shRNA transduction 3.2.10.2
Plasmid pLKO.1 vectors (Figure 3-2) encoding shRNAs targeting the human fibulin-1 gene 
(SHCLNV-NM_001996) were kindly provided by Frank Buchholz as E.coli glycerol stocks. To 
expand, plasmid DNA stocks were defrosted, 250 ml liquid LB-medium was infected and 
incubated at 37°C overnight under constant shaking. Plasmid DNA was isolated using the 
QIAGEN Plasmid Kit with QIAGEN-tip 500 according to manufactures instruction. Plasmid 
quality and amount were determined on a NanoDrop 200 UV-Vis spectrophotometer.  
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Figure 3-2: pLKO.1-puro vector map  
Vector map shows the schematic construction of the pLKO.1-puro vector, including the cloning site for 
shRNA constructs as well as regions for puromycin and ampicillin resistance. In combination with an origin 
of replication (ori), it is possible to expand the vector and effectively select only transfected bacteria. 
Puromycin resistance mediates selection of transduced eukaryotic cells. Additionally, vector structure 
allows for lentiviral particle production (vector map adapted from: sigmaaldrich.com).   
  
To produce lentiviral vector particles, HEK293T cells were transfected with pLKO.1 plasmid that 
were either empty or contained shRNA 10 or shRNA 11 in combination with the packaging 
plasmids psPAX and pVSVg using PEI. After 48 h of growth in IMDM medium, the lentiviral 
vector containing media supernatants were collected, and SCP-1 wildtype (WT) cells were 
infected twice by adding the supernatant to previously PBS washed cells. The medium 
containing the lentivirus vector was supplemented with 1 µg/ml protamine and incubated for 1 h 
and fresh DMEM medium with 10% FCS was added in at a ratio of 1:1. This procedure was 
repeated after 12 h. Sequences of the shRNAs 10 and 11 are shown in Table 3-9.  
 Western blot 3.2.10.3
After washing the decellularised ECM twice with ice-cold PBS, the protein layer was detached 
using 100 µl/cm2 M-Per mammalian protein extraction reagent and the Halt protease inhibitor 
cocktail at a ratio of 10:1 (v/v). Using a cell scraper, the ECM was sheared, transferred into 
reaction tubes, and centrifuged at 14,000 g for 7 min. Supernatant was collected and protein 
concentration determined using the Pierce Bicinchoninic Acid (BCA) protein assay kit according 
to the manufacturer’s instructions. A standard curve was prepared using BSA (0, 0.2, 0.4, 0.6, 
0.8, 1 and 1.5 mg/ml) as standard, provided in the kit. Working reagent and samples were added 
into microplate wells at a ratio of 20:1 (v/v) and incubated for 45 min at 37°C. The absorbance of 
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bicinchoninic acid-Cu+ chelate complex was measured at 570 nm using a plate reader. A 
representative standard curve and linear regression curve are shown in Figure 3-3. 
   
Figure 3-3: BSA assay standard curve 
Representative image of a standard curve estimation for BCA assay. 
 
Isolated proteins (7 μg) were separated by SDS-PAGE on 7.5% acrylamide gels in duplicate. As 
loading control, one gel was stained with Coomassie blue solution (0.25% Coomassie blue 
dissolved in 45% methanol and 10% acetic acid) for 10 min. Destaining was performed by 
incubating the gels in a solution containing 45% methanol and 10% acetic acid for 1 h, and in 
distilled water overnight. The gel was imaged using Syngene G:Box and the Prestain Protein 
Ladder PAGE Ruler was used as the marker. 
Protein transfer onto 0.45 μm nitrocellulose membranes was performed for 1h at 15 V and 3 A. 
Membranes were blocked for 1 h in blocking solution consisting of 5% milk powder (Carl Roth, 
Germany) dissolved in 10% Tris-buffered saline (1.5M NaCl, 30mM KCl, 250mM Tris, pH 7.4, all 
Carl Roth, Germany) containing 0.05% Tween 20 (TBST, Carl Roth, Germany). Incubation with 
fibulin-1 antibody (rabbit anti-human IgG, 1:800 in blocking solution, Santa Cruz Biotechnology, 
USA) occurred overnight at 4°C. Anti-rabbit IgG conjugated to horseradish peroxidase (1:5000 in 
blocking solution, GE Healthcare, UK) was applied as secondary antibody for 1h. Visualization of 
antigen-antibody complexes was performed with ECL plus western blotting detection reagents 
(Amersham, UK) and chemiluminescence was analyzed on a LAS-3000 imager (FUJIFILM, 
Japan). Semi-quantification was performed using the ImageJ software (1.47v, National Institutes 
of Health, USA) using SCP-1 WT signal as reference. 
 ELISA 3.2.10.4
To assess SDF-1 secretion levels, cells were seeded in 6-well plates at a density of 15,000 
cells/well and medium changed after 24 h. Cells were cultured in standard or osteogenic 
medium, the supernatant collected after different time points (1 d, 2 d, 5 d, 7 d), and frozen at -
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80°C before analysis. The ELISA assay was performed using reagents from the DuoSet ELISA 
Development kit for SDF-1 according to the manufacturer’s protocol. Absorbance was measured 
on a microplate reader (Anthos htII) at 405 nm with reference wavelength at 570 nm. SDF-1 
concentrations were calculated from optical density values using a calibration curve. All assays 
were performed in duplicate. 
3.2.11 Statistical analysis 
All results are presented as mean ± standard error of the mean (SEM) or standard deviation 
(SD). All experiments were performed independently at least thrice with the exception of SDF-1 
ELISA, which was performed in duplicate. Means were compared using the Students two-tailed 
unpaired t-test and variance was analyzed using ANOVA, both in GraphPad prism software 
(ver.5.0). A p-value ≤ 0.05 was considered statistically significant. 
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4 Results 
We adapted and applied a technique, published by Prewitz et al. 2013, to mimic the HSPC niche 
with respect to the extracellular compartment of the human BM. We used decellularized ECM 
scaffolds derived from SCP-1 cells, a human MSC cell line. We found that these ECMs are 
supportive substrates for HSPC proliferation and cell expansion. Moreover, CD34+ HSPCs were 
found to be a heterogeneous population of adherent and non-adherent cells. After cells adhere 
via the ITGβ3, ITGαIIb, and ITGαV (RGD-receptors), they adapt to the biochemical and 
biomechanical properties of the ECM and show cell stiffening and migratory morphology.  
 Extracellular matrix scaffolds for HSPCs 4.1
ECM scaffolds are cell-free protein layers secreted by growing cells and covalently bind to 
specialized glass surfaces. To produce ECM scaffolds for HSPCs, SCP-1 cells were seeded 
onto glass surfaces at a density of 1 x 104 cells/cm². After reaching confluency, cells were 
cultured for another 5 to 7 days before decellularization by osmotic shock. The quality of the 
remaining macromolecular protein structure was visualized and assessed for ECM delamination 
using inverted microscopy (Figure 4-1). 
 
Figure 4-1: Decellularization process for ECM generation 
Phase contrast images and corresponding cartoons show the process of decellularization. SCP-1 cells 
were grown to confluency on a glass substrate. After an additional culture period of up to 7 days, cells 
were decellularized using ddH2O treatment for up to 15 min under slight and continuous shaking 
(Decellularization). The macromolecular protein meshwork (cell-free ECM) remains covalently bound on 
the surface of the glass slide (ECM). Bars = 200 µm.  
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4.1.1 ECM properties  
Prewitz et al. (2013) reported that ECMs derived from BM isolated MSCs were approximately 
1 µm in height when cells were cultured in standard DMEM supplemented with 10% FCS for 10 
days after confluency. These ECMs showed soft material properties with an elastic modulus of 
approximately 10 to 10³ Pa, which is in the range of human BM measured by AFM indentation 
(Jansen et al., 2015). Surface distribution of the ECM was approximately 10% when cells were 
cultured on PCD without surface coating but was up to 95% when POMA-coated glass surface 
were used. Using mass spectroscopy, Prewitz et al. (2013) detected more than 500 proteins, 
including, structural constituents in the ECMs, such as fibronectin, collagen, and GAGs,. 
Moreover, they also found that classical MSCs secreted and released cytokines like HGF, FGF, 
VGF, and IL-8; all of these molecules participate in regulating the HSPC niche (Prewitz et al., 
2013, 2015).  
In this study, using the same anchoring method but with a different decellularization technique, 
ECM preparations derived from SCP-1 cells remained covalently bound to the copolymer- 
(POMA) and FN-coated glass surfaces (Figure 4-2A), indicating, applicability to multiple cells 
and cell lines. Contrarily, when uncoated surfaces like conventional PCDs were used, we 
observed delamination of ECM proteins upon decellularization (Figure 4-2B). The scaffolds 
generated by us were found to be approximately 1 µm in height, as measured by z-scan 
confocal microscopy. However, by probing different areas on a single ECM layer, enormous 
differences in ECM height could be detected ranging from 100 nm to 5 µm. Thus, ECM scaffolds 
derived from SCP-1 cells possess similar features to those derived from MSCs, as described by 
Prewitz et al. (2013). 
 
Figure 4-2: ECM lateral distribution after decellularization 
(A) Phase contrast images of ECM structure on POMA-coated glass surfaces show up to 100% lateral 
ECM distribution. (B) Phase contrast images of ECM structure on uncoated PCD surfaces shows ECM 
delamination (asterisks = areas of ECM delamination from surface). Bar = 200 µm. 
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4.1.2 HSPC survival in ECM and PCD cultures 
Human G-CSF mobilized peripheral blood was used to obtain useable numbers of HSPCs. 
Healthy volunteer donors were treated with G-CSF and apheresis was performed to concentrate 
HSPCs. However, for cultivation, cells needed to be further enriched due to excessive leukocyte 
contamination (Figure 4-3A). HSPCs were isolated using the immuno-magnetic bead separation 
technique where antibodies against the surface antigen CD34, bound to a magnetic bead, were 
used to label HSPCs. Cells were then trapped in a strong magnetic field, washed, and eluted. 
The CD34+-cell proportion was regularly tested using flow cytometry and cells were used when 
purity was above 95%. CD133, an additional HSPC marker, was counterstained to visualize 
stem cell heterogeneity (Figure 4-3B). 
 
Figure 4-3: Stem cell marker expression on freshly isolated HSPCs 
(A) Separation of PB leukocytes by flow cytometry. Scatter light forward scatter (FSC) and side scatter 
(SSC). Lym = lymphocytes including HSPCs (~40%), Mon = monocytes (~5%) and Gran = granulocytes 
(~55%). (B) Freshly isolated CD34+ HSPCs in scatter showed an enriched population of cells. Cells were 
stained for stem cell surface markers CD34 and CD133 using antibodies. Approximately 97% of freshly 
isolated HSPCs were found CD34+ and approximately 74% showed CD133 expression. 
 
Isolated HSPCs were seeded at a density of 1 x 104/cm² on ECM scaffolds in serum-free 
CellGro culture media. At  less than 12 h after seeding, we observed clustered adhesion of 
HSPCs to the underlying substrate using bright field microscopy (Figure 4-4A). Remarkably, only 
about 20% of CD34+ HSPCs adhered (AT-cells) to the ECM proteins, indicating a strong 
heterogeneity in the HSPC pool of PB-derived cells. The remaining cells remained in the 
supernatant (SN-cells). In parallel, we performed classic expansion cultures using PCDs where 
cells were cultured in suspension and no adhesion to plastic surfaces could be detected.  
To quantitate cell survival in both these conditions, cells were stained with DAPI at different time 
points and detected by flow cytometry (Figure 4-4B). Freshly isolated HSPCs were found to 
show highest DAPI fluorescence with approximately 1.1% dead cells due to intensive handling 
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during their isolation. After 5 days in ECM culture or PCD culture, we detected decreased 
amounts of DAPI+ cells (Figure 4-4C). This was true at days 7 and 11compared to freshly 
isolated cells (Figure 4-4C). In PCD cultures, a DAPI signal was obtained in less than 1% of 
cells. In general, we found very low numbers of dead cells, indicating cell survival consistent with 
proliferation.  
 
Figure 4-4: HSPC survival cultured on ECM scaffolds 
(A) Representative phase contrast images and corresponding cartoon of CD34+ HSPCs seeded onto ECM 
for 12 h (red arrows indicating clustered accumulation). Bar = 200 µm. (B) Representative flow cytometry 
panel for DAPI staining for detecting dead cells. Scatter light indicates enriched cell population in the 
lymphocyte and single cell gates. DAPI+ cells are dead cells. (C) Quantification of percent DAPI+ cells; 
n = 4, two-tailed t-test, no significant differences between groups. Error bars denote SEM. 
 
4.1.3 HSPC expansion in ECM and PCD cultures 
As mentioned before, HSPC were classified as either AT-cells or SN-cells after less than 12 h in 
ECM culture. As enumerated by absolute cell counts, we found both populations to be actively 
proliferating. After 5 days in culture, TNCs expanded by 3-fold, which represented a significantly 
higher expansion compared to PCD cultures (1.5 fold, p < 0.05). By increasing the culture period 
to 7 or 11 days, TNC numbers cultured on ECM increased by respectively 7.2-fold and 13-fold, 
on average. Notably, the number of AT-cells did not further increase after 7 days (Figure 4-5A). 
In contrast, PCD-cells expanded remarkably less during the same time. After a culture period of 
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7 or 11 days, expansion of TNCs in PCD cultures was 4.8-fold (p < 0.01) and 7.5-fold (p < 0.01), 
respectively (Figure 4-5A). In addition, using flow cytometry, we found that after 5 days, ECM 
scaffolds significantly expand CD34+ HSPCs (by 1.8 fold) compared to only maintenance of 
CD34+ HSPCs in PCD cultures (p < 0.05). Similarly, at 7 and 11 days, CD34+ cells expanded by 
up to 4.5-fold in ECM culture but only up to 1.9-fold in PCD cultures (p < 0.01). Interestingly, 
expansion of CD34+ cells stagnated after 7 days, indicating this time point as the limit of HSPC 
expansion culture due to nutritional turnover (Figure 4-5B). After removing SN-cells, we 
monitored the proliferation of AT-cells and the repopulation of the supernatant fraction by bright 
field microscopy, which showed only further division but no increase in adhesion. Similar findings 
have been reported by by Jing et al. (2010) using a MSC-HSC co-culture in vitro model. From 
these findings, we conclude that our ECM scaffolds provide additional pro-expansive factors 
during HSPC culture. 
 
Figure 4-5: HSPC expansion on ECM substrates and PCD 
(A) In vitro TNC expansion on ECM or PCD culture for 5, 7, and 11 days. Histogram bars represent fold 
change in relation to starting cell number (black line). AT-cells are shown as percentage share of total 
counted cells; n = 5, two-tailed t-test, significance in comparison to ECM culture. (B) CD34+ cell 
expansion on ECM or PCD culture for 5, 7, and 11 days. Histogram bars represent fold change in relation 
to starting cell number (black line). AT-cells are shown as percentage share of counted cells; n = 5, two-
tailed t-test, significance in comparison to ECM culture. Error bars represent SD; *p < 0.05, **p < 0.01, 
***p < 0.001.   
 
To gain further understanding of the impact of culture conditions (PCD or ECM) and the state of 
division of AT-cells or SN-cells, we performed CFSE generation tracking using flow cytometry. 
Figure 4-6A shows representative CFSE intensity histograms of AT-, SN- and PCD-cells after 5 
days of culture. Freshly isolated CD34+ HSPCs that were labeled with CFSE served as control 
(generation 0). We found up to 6 generations in both culture conditions. However, PCD-cells had 
undergone lesser number of cell divisions compared to ECM-cells, as observed by the 
heterogeneous peak distribution. 
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To further quantify the cell divisions, 3 independent experiments were performed. AT- and SN-
cells had predominantly undergone 5-6 divisions in around 80% of all AT-cells and in 70% of all 
SN-cells. Surprisingly, AT-cells showed greatest proliferation as 55% of AT-cells divided 6 times 
compared to only 30% of SN-cells (Figure 4-6B). Contrarily, only approximately 10% of PCD-
cells divided 6 times, which is in line with the aforementioned lower expansion rate. Accordingly, 
significantly lower numbers of AT- and SN-cells were found in generations 1-3 (p < 0.05) 
compared to PCD-cells (Figure 4-6B). Furthermore, flow cytometry was used to separate CD34+ 
HSPC from differentiated cells in every generation and remarkably, no significant differences 
could be detected between the classical PCD expanded HSPCs and ECM expanded HSPCs 
(Figure 4-6B), further strengthening evidence for the ECM as a HSPC-supportive culture 
substrate. 
 
Figure 4-6: CFSE generation tracking of HSPCs cultured on ECM or PCD after 5 days 
(A) Representative CFSE-intensity histogram showing distribution of cell generations of CD34+ (red) and 
CD34- (green) cells after 5 days in ECM (AT-cells and SN-cells) or PCD (PCD-cells) culture. Freshly 
isolated cells (blue) served as control (generation 0). (B) Proportion of TNCs (left) and CD34+ cells (right) 
detected in cell generations (0 - 6) after 5 days in ECM or PCD; n = 3, two-tailed t-test; * = AT-cell and 
+ = SN-cell significance in comparison to PCD. Error bars represent SD.; *p < 0.05, **p < 0.01, ***p < 
0.001. 
 
As AT-cells divided most, we aimed to identify cell cycle phases in AT- and SN-cells using flow 
cytometry. Figure 4-7A shows a representative flow cytometry experiment of BrdU/PI 
incorporation. Cells with low PI and BrdU intensity are defined as G0/G1 cells. Through DNA 
synthesis in the S phase, cells incorporate BrdU and appear BrdU positive. G2/M phase cells do 
not incorporate BrdU as DNA was synthesized in S phase but increase PI intensity. According to 
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the BrdU incorporation assay after 5 days of culture, AT-cells were predominantly in the cycling 
G0/G1 phase (79.3% ± 5.4%), followed by S-phase (18.5% ± 3.9%), and significantly lower 
number of cells were detected in G2/M phase (1.9% ± 1.4%). Comparatively, SN-cells were 
63.4 ± 3.4% in G0/G1, (p < 0.01); 11.8% ± 2.9%, (p < 0.05) in S phase, 25.4% ± 6.8%, (p < 0.01) 
in G2/M phase (Figure 4-7B). As PB mobilized HSPCs were all found in G1/G0 phase (Uchida et 
al., 1997), it is possible that ECM contact supports synchronized proliferation of AT-cells.  
 
Figure 4-7: BrdU incorporation assay of 5 days ECM expanded HSPCs 
(A) Representative flow cytometry dot-plots of 5 day expanded HSPCs on ECM scaffolds. Scatter light plot 
represent heterogeneous population of cells. BrdU- and PI-staining represent cells in G0/G1, S, and G2/M 
cell cycle phases, respectively. (B) Quantification of cell cycle phases in SN- and AT-cells after 5-day 
ECM culture; n = 3, two-tailed t-test. Error bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001.   
 
 HSPC morphological and mechanical adaptation to ECM 4.2
As contact with ECM scaffolds or MSC feeder-layers strongly influence HSPC shape (Freund et 
al., 2006b; Fonseca et al., 2010; Reichert et al., 2015) we investigated how SN- and AT-cells 
differ in terms of morphology. AT-cells displayed a heterogeneous phenotype with regard to cell 
shape (Figure 4-8A). Specifically, some cells showed an elongated morphology forming a 
magnupodium or lamellipodium at their front pole and an uropod at their rear pole, while others 
displayed a spherical shape with either a smooth surface or developed numerous protrusions on 
their surface (Figure 4-8B). Interestingly, some cells were flattened such that they appeared with 
one face in the ECM upon bright field microscopy; no uropods could be detected in these cells 
(Figure 4-8A). Contrarily, SN-cells remained spherical during the culture period, similar to those 
found in PCD cultures (Figure 4-8C).  
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Figure 4-8: AT- and SN-cell morphology in ECM culture 
(A) Representative phase contrast image of AT-cells on ECM showing different morphologies (purple 
arrowheads indicating flat cells). Bar = 40 µm. (B) Representative phase contrast images of AT-cells on 
ECM showing elongated cells forming a magnupodium (green arrowhead) or lamellipodium (red 
arrowhead) at their front pole and an uropod (yellow arrowhead) at the rear pole. Spherical adhered cells 
displayed either a smooth surface or developed numerous protrusions (yellow arrow). Bar = 10 µm. (C) 
Representative phase contrast images of SN-cells (upper image) or PCD cultured cells (lower image) 
showing spherical shape. Bar = 10 µm. 
 
4.2.1 Actin polymerization and polarization  
Morphological adaptation towards a polarized phenotype, as detected in AT-cells, mostly 
depends on cytoskeletal rearrangement. As polarization indicates migration, we focused on the 
actin cytoskeleton as it contributes to cell motility and adhesion. To analyze actin cytoskeletal 
arrangement, we performed immunofluorescence staining of the filamentous actin (F-actin) and 
found stress fiber formation along AT-cells. This was true in ECM as well as MSC co-cultured 
AT-cells (Figure 4-9A-B). Interestingly, on ECM, these fibers were mostly polarized towards the 
front end of the cells, indicating migration in this direction (Figure 4-9A). In SN-cells, we detected 
F-actin only around the cell membrane as a cortical actin belt (Figure 4-9A).  
 
Figure 4-9: F-actin polarization on AT- and SN-cells 
(A) Representative confocal microscopy images of the f-actin cytoskeleton using phalloidin-488 (green) 
and nuclear DAPI (blue) staining. AT-cells show a polarized phenotype and stress fiber formation towards 
a lamellipodium. SN-cells show cortical localization of f-actin fibers. Bars = 5 µm. (B) Representative 
confocal microscopy images of the f-actin cytoskeleton using phalloidin-488 (green) and nuclear DAPI 
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(blue) staining. Freshly isolated HSPCs (104 cells per cm²) were seeded to a confluent layer of SCP-1 
cells. After 5 days in culture, AT-cells show stress fiber formation (asterisks). Arrow indicates actin staining 
of one SCP-1 cell. Bar = 10 µm. 
 
4.2.2 Biomechanical phenotype 
During stem cell mobilization, HSPCs undergo multiple steps of mechanical rearrangement. 
Further, as G-CSF stimulation leads to proliferation of BM HSPCs, the cytoskeleton needs to be 
remodeled in preparation for cell division. Furthermore, the intravasation of HSPCs into the 
blood stream requires cell softening so that these cells can pass through the basal membrane 
and the endothelial cell spaces. Once in the blood stream, HSPCs are exposed to blood 
pressure that also requires cytoskeletal adaptation. Thus, to analyze the mechanical phenotype 
of PB HSPCs and BM HSPCs, we used real-time deformability cytometry where shear stress 
was applied to cells in a microfluidic channel constriction and resulting deformation and cell size 
recorded in real-time. This technique is based on image processing and allows the optical 
validation of cell shape and morphology (Otto et al., 2015). In Figure 4-10A, representative 
images of freshly isolated CD34+ HSPCs from PB are displayed while passing through the 
channel constriction. Freshly isolated cells, either from the PB or the BM, were found to be 
homogeneous in cell-size (range: 50-60 µm²) and shape. Importantly, they remained nearly un-
deformed, reflecting a stiff phenotype. However, BM HSPCs showed heterogeneity in cell size 
and deformability (Figure 4-10B), which reflects the aforementioned mechanical remodeling 
processes. 
 
Figure 4-10: Freshly isolated PB and BM CD34+ HSPCs measured in RT-DC 
(A) Heat-plot of cell size and deformation of freshly isolated PB CD34+ HSPCs in RT-DC. Cells appear as 
a homogenous population. Phase contrast images represent cells passing through the channel 
constriction. (B) Representative heat-plots of cell-size and cell-deformation in CD34+ HSPCs from PB or 
BM. Contour plot shows direct comparison of both populations by highlighting 95% (outer line) and 50% 
(inner line) density. 
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Furthermore, we investigated how SN- and AT-cells differ from each other and PCD-cells in 
terms of physical parameters. Next, to validate our results, we also tested the same with SCP-1-
co-cultured HSPCs. Interestingly, ECM-cultured and SCP-1 co-cultured AT-cells exhibited 
macroscopically denser intracellular packaging and accumulation of granular structures 
compared to SN-cells, which might be associated with the aforementioned F-actin structure 
(Figure 4-11A). Upon culture on ECM scaffolds, cells became larger with an average cell size of 
approximately 104.1  7.3 µm². In contrast, SCP-1 co-cultured cells were smaller with an 
average cell-size of 80.8  1.4 µm² (p < 0.001; Figure 4-11B and C). However, cell-size of ECM-
cultured (p < 0.001) and SCP-1 co-cultured (p < 0.001) cells significantly differed from freshly 
isolated CD34+ HSPCs (Figure 4-11B and C). For active proliferation in ECM culture and SCP-1 
co-culture, cells had to initially grow before subsequent cell division. A comparison of 
deformability of ECM-cultured AT-cells and SN-cells showed that AT-cells had a significantly 
less deformable phenotype (d = 0.041  0.006 vs. 0.056  0.003; p < 0.01). This was also true 
for SCP-1 co-cultured HSPCs (AT-cells, d = 0.034  0.005; SN-cells, d = 0.055  0.007; p < 
0.05) (Figure 4-11B and C). Interestingly, deformation in AT-cells did not significantly differ from 
freshly isolated CD34+ cells (d = 0.034  0.006; p > 0.05) while that of SN-cells was remarkably 
higher than freshly isolated cells (p < 0.001; Figure 4-11B and C). Nevertheless, SN-cells were 
comparable to classical suspension cultured PCD-cells with regard to cell size and deformation 
(Figure 4-11D). 
Taken together, our data indicate that adhesion to ECM-proteins remodels HSPCs towards a 
more naïve morphological and mechanical phenotype, pointing perhaps to functional equality.  
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Figure 4-11: HSPC biophysical properties in ECM, SCP-1 co-culture, and PCD culture 
HSPCs were cultured in ECM, as SCP-1 co-cultures, or PCD cultures. After 5 days, cell size and 
deformation were analyzed using RT-DC. (A) Representative images of ECM- and MSC co-cultured cells 
deformed through microfluidic channel constriction. (B) Representative heat-plots of cell-size and cell-
deformation of ECM- and SCP-1 co-cultured AT- and SN-cells. Contour plots highlight 95%- (inner line) 
and 50%- (outer line) density of freshly isolated (Fresh), AT- and SN-cells. (C) Histogram bars 
representing RT-DC analyses of deformation and cell-size of freshly isolated cells (Fresh) and ECM- or 
SCP-1 co-cultured cells; n = 5, linear mixed model analysis, Error bars denote SD; *p < 0.05, **p < 0.01, 
***p < 0.001. (D) Representative RT-DC scatter plot of PCD-cells (PCD donor 1 (orange) and PCD donor 
2 (green)). Contour plot overlay highlights 95%- (inner line) and 50%- (outer line) density of PCD cells, 
SN-cells (red) and AT-cells (black). 
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 Bioactive SDF-1 is incorporated in ECM scaffolds 4.3
The SDF1/CXCR4 axis is the most commonly investigated chemokine axis in hematology and is 
known to be essential for homing and retention of HSPCs in the BM (Peled et al., 1999; Petit et 
al., 2002). SDF-1 is largely secreted by BM MSCs and incorporated into the ECM. Additionally, 
an SDF-1 gradient is established upon its transport through endothelial cells into the blood 
stream and it serves to orient and direct HSPCs into the BM. CXCR4 serves is a major receptor 
expressed by HSPCs during this process. Therefore, we asked whether SDF-1 is involved in the 
adhesion of HSPCs to ECM scaffolds.   
Prewitz et al. (2013, 2015) have previously demonstrated that amongst various morphogens, 
SDF-1 can be retrieved from decellularized ECMs derived from human BM-MSCs. To test 
whether SCP-1 cells secrete bioactive SDF-1 and if this is anchored to the ECM proteins, we 
performed immunostainings for SDF-1 and CXCR4 after 5 days of culture on ECM. Using 
confocal microscopy, we detected CXCR4 expression in AT- and SN-cells. Specifically, while 
SN-cells showed a predominantly membranous expression pattern, AT-cells exhibited both 
cytosolic and membranous CXCR4 expression. Further, we detected AT-cells with intracellular 
SDF-1 using identical experimental settings for SDF-1, which points towards SDF-1 
internalization by active recognition and uptake from the ECM scaffold (Figure 4-12, upper 
panel). Contrarily, SN-cells did not stain for SDF-1. In Figure 4-12, the schematic illustrations 
portray a hypothesized situation for AT- and SN cells cultured on ECM. Nevertheless, as SN-
cells express CXCR4, they must be able to recognize SDF1 within the supernatant. In order to 
assess SDF-1 processing within SN-cells, we added exogenous SDF-1 at varying 
concentrations to the medium. The lower panel of Figure 4-12 illustrates the expected uptake of 
SDF-1 from the supernatant. Upon exogenous addition of SDF-1, we found CXCR4 and SDF-1 
to be localized in the cytosol of SN-cells, indicating internalization of ligand-receptor-complex by 
active recognition of recombinant SDF-1 by CXCR4 (Figure 4-12, lower panel).   
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Figure 4-12: Bioactive SDF-1 is incorporated into ECM scaffolds and is recognized by AT-cells 
Representative confocal microscopy images of CXCR4 (red) or SDF-1 (green) staining and nuclear DAPI 
(blue) staining. Cells were cultured for 5 days on ECM scaffolds and treated either without (w/o) or with 
exogenous SDF-1 in the culture medium. Schema illustrates experimental settings. Bars = 5 µm.   
 
Interestingly, increased adhesion of HSPCs was not induced via additional SDF-1 treatment 
(Figure 4-25B). Our results show that SDF-1 is incorporated in the SCP-1 cell-derived ECM 
scaffolds and that it can be actively recognized and internalized by HSPCs.  
4.3.1 CXCR4 polarization towards ECM 
To further determine SDF-1 function in ECM scaffolds, we analyzed the distribution of CXCR4 
on AT-cells using Z-stack imaging in confocal microscopy. CXCR4 is described to be polarized 
to the leading edge of CD34+ HSPC when cultured in media containing serum on PCD (Giebel et 
al., 2004). These authors also reported polarized distribution of several CD markers like CD43, 
CD44, CD50, and CD54 in the uropod of plastic adherent HSPCs, similar to findings in 
peripheral leukocytes (Sánchez-Madrid and Del Pozo, 1999). Therefore, we asked whether 
recognition of SDF-1 within the ECM scaffolds by CXCR4 expressed on the cell surface is 
associated with cell polarization.  
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In our experiments, AT-cells were stained for CXCR4 and DNA was counterstained using DAPI. 
In z-stack microscopy, HSPCs were virtually divided into three planes, namely, top = I, 
middle = II, and bottom = III planes (Figure 4-13). Using ECM scaffolds during culture, we 
detected the greatest amount of CXCR4 at the bottom of cells when in contact with ECM, as the 
fluorescence signal steadily increased from planes I to III (Figure 4-13A). We also observed an 
intensive intracellular CXCR4 localization. However, we also detected a vertical but not a lateral 
polarization, as described by Giebel et al. (2004). To test whether this phenotype represents 
SDF-1 localization, we added an additional 10 ng/ml recombinant SDF-1 to the supernatant. 
Interestingly, this resulted in the suppression of CXCR4 polarization, which indicates that 
polarization of CXCR4 is triggered by the local concentration of SDF-1 within the ECM scaffolds. 
To further confirm this, we analyzed CXCR4 polarization after adhesion of HSPCs to SCP-1 
cells. SCP-1 cells were found to both produce and secrete SDF-1 (Figure 4-30) into the 
supernatant at a concentration that was 50-fold lower than that of the exogenously added SDF-
1. Remarkably, under these conditions, we also found identical polarization of CXCR4 towards 
the SCP-1 cell layer (Figure 4-13). This shows that SDF-1 released by the SCP-1 cells is 
incorporated into the ECM scaffold and stored during the 5 days of culture, and that AT-cells 
polarize CXCR4 towards the prevalent SDF-1 gradient.  
 
Figure 4-13: CXCR4 is polarized towards the ECM on AT-cells 
Representative confocal microscopy z-stack images of α-CXCR4 (red) and nuclear DAPI (blue) staining. 
I = top, II = middle, and III = bottom planes of cells. (A) Cells were cultured in medium without (w/o) 
additional SDF-1. Scheme shows cutting planes and SDF-1 (green arrowheads) incorporation in the ECM. 
(B) Cells were cultured in medium supplemented with additional exogenous SDF-1 (10 ng/ml). Scheme 
shows cutting planes and SDF-1 (green arrowheads) suspended in supernatant and incorporated into 
ECM scaffolds. (C) Cells were co-cultured with a layer of SCP-1 cells in medium without (w/o) additional 
SDF-1. Schema shows cutting planes and SCP-1 cell layer. Bars = 5 µm. 
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 HSPC integrin expression and migration 4.4
The interaction of cells with the surrounding ECM components is primarily mediated through 
integrin signaling through formation of focal contacts (Hynes, 2002). However, to recognize 
adhesive sides on ECM proteins, the alpha and beta subunits of the integrins need to hetero-
dimerize and be activated. Several integrins are known to be activated via the CXCR4/SDF-1 
signaling axis, e.g. LFA-1 (CD11a), VLA-4 (CD49d), and VLA-5 (heterodimer of CD49d and 
CD29). Such integrins then mediate endothelial adhesion and trans-endothelial migration (Peled 
et al., 2000) while others retain HSPCs in the BM (Wagers et al., 2002) and are associated with 
quiescent and long-term repopulating cells (Table 4-1).  
Table 4-1: Integrins described as being HSPC-related. 
 
Integrin CD Gene Name 
Ligands  
(in heterodimeres) 
HSPC Function 
α4 CD49d ITGA4 Fibronectin VCAM-1 
BM homing, BM engraftment, maintenance, 
blocking leads to mobilization (Prosper et 
al., 1998; Wagers et al., 2002)  
α5 CD49e ITGA5 
Fibronectin 
Osteopontin 
BM lodging via osteopontin binding (Barry 
et al., 2000; Nilsson et al., 2005)  
α6 CD49f ITGA6 Laminin Blocking leads to reduced BM homing (Qian et al., 2006)  
αIIb CD41 ITGAIIb Fibronectin 
Early hematopoiesis, BM lodging, 
regulation of progenitor number (Berridge 
et al., 1985; Corbel and Salauen, 2002; 
Emambokus and Frampton, 2003)  
αV CD51 ITGAV 
Fibronectin 
Vitronectin 
Tenascin 
HSPC maintenance (Umemoto et al., 2012)  
β1 CD29 ITGB1 
Collagen Laminin 
Fibronectin 
Osteopontin 
BM lodging, differentiation (Williams et al., 
1991; Teixido et al., 1992)  
β3 CD61 ITGB3 Fibronectin Maintenance (Umemoto et al., 2006, 2008, 2012)  
 
4.4.1 Integrin surface expression on HSPC subsets  
We asked whether integrin expression differed among freshly isolated PB HSPCs, AT- and SN-
cells derived from ECM or SCP-1 co-cultures. We used flow cytometry to identify surface 
expression of HSPC-related integrins, namely CD29, CD41, CD49d, CD49e, CD49f, CD51, and 
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CD61 (Table 4-1). Expression screening was done using the panel represented in Figure 4-16, 
upper row. No significant differences could be identified between these groups of cells in terms 
of CD29, CD49d, CD49e, and CD49f surface expression. However, remarkably, 22.9%  6.3% 
of AT-cells expressed ITGIIb, whereas only 6.7%  5.2% of SN-cells and 3.4%  2.8% of 
freshly isolated cells were ITGIIb-positive. Moreover, 22.7%  6.6% of AT-cells showed ITGV 
expression and 41.5%  14.7% were positive for ITG3. In contrast, 6.7%  3.4% and 16.1%  
9.4% of SN-cells were positive for ITGV and ITG3, respectively. Accordingly, a minority of 
freshly isolated cells, 5.8%  4.2% and 3.9%  2.6%, were positive for ITGV and ITG3, 
respectively (Figure 4-14A). Slightly different results were obtained in SCP-1co-cultured HSPCs 
as greater numbers of ITGV-positive cells were encountered; however, the effect was the 
same as on ECM-cells (Figure 4-14B).  
 
Figure 4-14: Integrin surface marker expression on cultured and freshly isolated CD34+ cells 
Flow cytometry analyses of integrin surface marker expression of (A) freshly isolated CD34+ cells and 5-
days ECM cultured SN- or AT-cells, or (B) freshly isolated CD34+ cells or 5-day SCP-1 co-cultured SN- 
and AT-cells; n = 4, two-way ANOVA with Bonferroni post-hoc test; + = significant when compared to 
freshly isolated cells. Error bars denote SEM; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.4.2 Focal contact formation  
Interestingly, these integrins are known to form RGD-motive recognition dimers (Hynes, 2002). 
Therefore, we checked if a heterodimere of ITGV and ITG3 is expressed on AT-cells, as it 
regulates HSPC engraftment and maintenance by forming focal contacts and promoting outside-
in (ECM to cell) signaling (Umemoto et al., 2012). Using confocal microscopy, we identified 
ITGV3 as being membrane-associated in AT-cells (Figure 4-15A), but  ITGV3 could not be 
detected in SN-cells. To prove active focal adhesion formation, we performed further 
immunostainings for vinculin and phosphorylated paxillin. Vinculin was found to be highly 
expressed in AT-cells and localized to the cytosol as well as membrane-associated (Figure 
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4-15A). As AT- and SN-cells expanded rapidly in ECM culture and vinculin is indispensable for 
HSPC repopulation (Ohmori et al., 2010), we also found vinculin expression in SN-cells (Figure 
4-15B). Paxillin, in contrast, was found to be phosphorylated at Tyr118 when membrane 
associated (Figure 4-15A and C) and was localized near the ITGV3 heteromer exclusively in 
AT-cells (Figure 4-15C, arrowheads). This indicates formation of activated signaling focal 
contacts through integrin mediated adhesion to the ECM proteins. 
 
Figure 4-15: Integrins recognize RGD-motives and promote active focal contact formation 
(A) Representative confocal microscopy images of α-ITGαVβ3 (left panel, yellow), α-vinculin (mid panel, 
red), α-p-paxillin (right panel, red), nuclear DAPI (blue) staining, merged and corresponding bright field 
images of 5 days cultured AT-cells, showing cortical localization of ITGαVβ3. Activated paxillin and 
vinculin are distributed throughout the cytosol. Bars = 5 µm. (B) Representative confocal microscopy 
images of α-vinculin (red), nuclear DAPI (blue) staining, merged and corresponding bright field image of 5-
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day cultured SN-cells showing cytosolic distribution of vinculin. Bar = 5µm (C) Representative confocal 
microscopy images of α-ITGαVβ3 (yellow), α-p-paxillin (right panel, red), nuclear DAPI (blue) staining, and 
merged and corresponding bright field images of 5-day cultured AT-cells. Arrowheads represent proximitry 
of ITGαVβ3 and p-paxillin in a cellular protrusion. Bar = 5 µm  
 
4.4.3 Integrin activation via ECM adhesion 
Our findings prompted us to investigate whether ECM scaffolds induce ITGβ3 expression within 
CD34+ cells or only enrich ITGβ3+ cells. FACS was used to sort CD34+ITGβ3- or CD34+ITGβ3+ 
cells from mobilized PB (Figure 4-16).  
 
Figure 4-16: FACS sorting panel for CD34+ ITGβ positive and negative cells  
Representative gating strategy for fluorescence activated cell sorting experiments for cells derived from 
PB. Lymphocytes and single cells were enriched using light-scatter. Dead cell exclusion was done by 
DAPI staining. Progenitor enrichment was done using the SSC-Alow/CD45dim and CD34+ gate. Sorting 
gates were CD34+ITGβ3- and CD34+ ITGβ3+. 
 
After culture for 5 days on ECM scaffolds, previously sorted CD34+ITGβ3+ or CD34+ITGβ3- 
HSPCs were analyzed for CD34 and ITGβ3 expression (Figure 4-17A). As expected, the sorted 
CD34+ITGβ3+ cells continued to exhibit strong ITG3 surface expression (55.4%  1.8%) when 
attached to ECM. However, only 31.2%  1.7% of previously sorted CD34+ITGβ3+ SN-cells were 
positive for ITG3. Interestingly, previously sorted CD34+ITGβ3- AT- and SN-cells showed 
upregulated ITG3 surface expression at 29.9%  11.9% and 19.8%  7.35%, respectively 
(Figure 4-17B and C). Along this line, CD34+ITGβ3+ sorted cells showed an increased adhesion 
capacity, compared to CD34+ITGβ3- cells. Up to 90 % of CD34+ITGβ3+ cells were found to 
adhere to ECM proteins after 12 h, as identified by phase contrast microscopy. However, sorted 
CD34+ITGβ3+ showed reduced proliferation and expansion from starting cell numbers (1.2  0.1 
fold) when cultured for 5 days on ECM-scaffolds (Figure 4-17D). On the other hand, 
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CD34+ITGβ3- cells proliferated significantly more, with 2.9  0.04 fold expansion (p < 0.0001), 
which is comparable to unsorted CD34+ cells cultured on ECM scaffolds for 5 days (Figure 
4-5C). Thus, our data suggest that ITGβ3 expression is induced by ECM preparations and that 
this is essential for effective adhesion. Interestingly, freshly isolated BM CD34+ HSPCs 
displayed the same ratio of ITGβ3+ cells as AT-cells (Figure 4-17E), which further strengthens 
our hypothesis that the ECM remodels the BM stroma with ITGβ3 as a major player in BM-ECM 
interactions. 
 
Figure 4-17: ECM scaffolds induce ITGβ3 surface expression 
(A) Schema represents work flow. CD34+ITGβ3+ and CD34+ITGβ3- HSPCs were FACS sorted from PB 
and cultured for 5 days separately on ECM scaffolds. SN- and AT-cells were found in both cultures and 
were analyzed for ITGβ3 expression by FACS. (B) Representative FACS plots for primarily sorted 
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CD34+ITGβ3+ and CD34+ITGβ3- cells after 5 days of culture on ECM scaffolds. AT- and SN-cells are 
shown according to CD34 and ITGβ3 surface expression. (C) Flow cytometry analyses of ITGβ3 surface 
expression in primarily sorted CD34+ITGβ3+ and CD34+ ITGβ3- cells after 5 days of culture on ECM 
scaffolds; n = 2, error bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001. (D) Fold-expansion in cell 
numbers from starting cell numbers of AT- and SN-cells of primarily sorted CD34+ ITGβ3+ and CD34+ 
ITGβ3- cells after 5 days of culture on ECM scaffolds; n = 2, two-tailed t-test; error bars denote SD; *p < 
0.05, **p < 0.01, ***p < 0.001. (E) BM aspirates of healthy donors were stained for CD34 and ITGβ3. 
Histogram bars represent proportion of ITGβ3+ cells in the total CD34+ HSPC population; n = 3, two-tailed 
t-test; error bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
4.4.4 Clonogenicity of ECM cultured HSPCs  
Beside maintenance in early hematopoiesis, ITG3 expression is a known differentiation marker 
and predominantly expressed during megakaryopoiesis (Naik and Parise, 1997;, Ficko, 2008) 
and erythropoiesis (Ferkowicz et al., 2003). Additionally, ITG3 was found to be essential for 
acute myeloid leukemia progression in mice (Miller et al., 2013). Therefore, ITG3 surface 
expression on the CD34+ HSPCs could also imply HSPC commitment. To verify clonogenicity of 
ECM cultured CD34+ HSPCs, we performed CFU-GEMM assays and compared them to those 
from freshly isolated CD34+ cells obtained from PB and BM using FACS (sorting panel 
presented in Figure 4-16). Interestingly, overall, BM CD34+ cells were found to form significantly 
fewer colonies compared to CD34+ PB-, CD34+ AT-, and CD34+ SN-cells (p < 0.01; Figure 
4-18A). However, CD34+AT-cells showed significantly more erythroid colonies with a mean of 
125 ± 19 colonies, including BFU-E and CFU-E, compared to 58 ± 12 colonies formed by CD34+ 
BM cells and 70 ± 14 colonies formed by CD34+ PB cells. No differences were found when 
compared to CD34+ SN-cells (114 ± 15 colonies; Figure 4-18B). These findings indicate a 
differentiation bias of CD34+ITGβ3+ cells towards the megakaryocyte-erythroid lineage. 
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Figure 4-18: CFU-GEMM colony formation of CD34+ cells  
(A) Histogram bars represent formation of colonies per 500 cells of CD34+ PB, BM, AT, and SN-cells. (B) 
Histogram bars represent formation of erythroid colonies (including CFU-E and BFU-E); n = 3 (including 3 
technical replicates), two-tailed t-test; error bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
To clarify whether this lineage differentiation bias is due to ITGβ3 surface expression, we 
performed clonogenicity assays with FACS-sorted CD34+ITGβ3+ (Figure 4-19A) and 
CD34+ITGβ3- (Figure 4-19B) cells derived from freshly isolated PB and 5 days ECM scaffold 
cultured AT- and SN-cells (Figure 4-19A and B). We identified that CD34+ITGβ3+ cells from ECM 
culture form predominantly erythroid colonies. Surprisingly, AT-cells formed remarkably fewer 
erythroid colonies compared to SN-cells and freshly isolated PB-cells (Figure 4-19A). 
CD34+ITGβ3- cells showed equal colony formation from all cell sources including all colony types 
(Figure 4-19B).  
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Figure 4-19: CFU-GEMM colony formation of PB-derived and ECM-cultured CD34+ITGβ3+ and 
CD34+ITGβ3- cells   
Histogram bars summarize colony formation after seeding 500 CD34+ITGβ3+ cells (A) and CD34+ITGβ3- 
(B) onto semi-solid CFU-GEMM medium; n = 3 (including 3 technical replicates), two-tailed t-test; error 
bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001.  
 
Moreover, PB-derived CD34+ITGβ3+ cells formed significantly more colonies than PB-derived 
CD34+ITGβ3- cells, indicating that these cells have an increased self-renewal and differentiation 
potential. However, overall colony formation by CD34+ITGβ3+ cells cultured on ECM did not 
reflect this potential (Figure 4-20A and B). Interestingly, CD34+ITGβ3+ SN-cells were found to be 
remarkably enriched in erythroid progenitors, as they formed the greatest number of colonies 
(Figure 4-20C). Additionally, between CD34+ITGβ3+ and CD34+ITGβ3- sorted cells, erythroid-
colony formation was significantly increased in all cell sources(Figure 4-20C).  
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Figure 4-20: CFU-GEMM colony formation by CD34+ ITGβ3+/ ITGβ3- cells 
(A) Representative images of colonies formed by the CFU-GEMM assay (166 cells seeded in semi-solid 
CFU-GEMM medium). (B) Histogram bars represent formation of all colonies (including CFU-E and BFU-
E, CFU-G, CFU-M, CFU-GM and CFU-GEMM) when 500 CD34+ITGβ3+ cells or CD34+ITGβ3- cells were 
seeded onto semi-solid CFU-GEMM medium. (C) Histogram bars represent formation of erythroid 
colonies (including CFU-E and BFU-E) when 500 CD34+ITGβ3+ or CD34+ITGβ3- cells were seeded onto 
semi-solid CFU-GEMM medium; n = 3 (including 3 technical replicates), two-tailed t-test; Error bars 
denote SD; * = significance when compared to corresponding CD34+ITGβ3+ cells, *p < 0.05, **p < 0.01, 
***p < 0.001.  
 
These findings indicate that CD34+ITGβ3+ cells cultured on ECM have a differentiation bias 
towards erythroid progenitors. The same cells, when freshly sorted from PB, also showed 
increased erythroid differentiation; however, colonies for other differentiation lineages were also 
increased compared to CD34+ITGβ3- cells. Thus, it is possible that ITGβ3+ surface expression is 
a marker for megakaryocyte-erythroid lineage commitment.        
4.4.5 HSPC migration when attached to ECM scaffolds 
As described above, ECM contact leads to morphological adaptations of AT-cells towards a 
polarized phenotype. Sánchez-Madrid and Del Pozo (1999) described this morphological 
adaptation as a migrative phenotype of PB leukocytes. In line with this description, HSPCs in 
contact with stromal cell feeder layers were described as a heterogeneous population of 
migrating and non-migrating cells (Reichert et al., 2015). Additionally, we have identified HSPCs 
to be highly interactive with each other, forming and abandoning cell-cell contacts (Figure 
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4-21A). Similar to previous findings, we also show that AT-cells need to be elongated or 
polarized to migrate, but are spherical when resting or not migrating on ECM (Figure 4-21A and 
B, Figure 4-8). However, AT-cells appear to be highly dynamic and vary between these two 
states. Using time-lapse microscopy, we found that dynamic plasticity of individual AT-cells such 
that they changed between the migratory and non-migratory phenotypes during an observation 
period of just 25 minutes. These dynamics were characterized as migration (migratory 
phenotype), resting (non-migratory phenotype) and continued migration (Figure 4-21B).  
  
Figure 4-21: AT-cell migration  
(A) Individual frames from 15 min time-lapse microscopy studies of migrating and interacting cells on 
ECM. Bar = 5 µm. (B) Individual frames from 25 minutes of time-lapse microscopy of a non-migrating cell 
and a migrating cell forming a non-migrating phenotype (asterisk). Bar = 5 µm. 
 
 Reduced migratory behavior via ITGαVβ3 inhibition 4.4.5.1
As we found that the ITGV3 heterodimer was most predominantly expressed and used for 
forming focal contacts on AT-cells, we asked whether this integrin heterodimer promotes 
migration. Using a blocking antibody for ITGV3 with an appropriate IgG control, we monitored 
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both migrating and non-migrating cells. Under both conditions the ratio of cells displaying the 
migratory or the non-migratory phenotype remained unchanged (Figure 4-22A and B).  
 
Figure 4-22: Ratio of migrating and non-migrating AT-cells 
Freshly isolated HSPCs (104 cells per cm²) were seeded onto an ECM scaffold. After 5 days in culture, 
cells were incubated for one hour with a blocking antibody directed against ITGαVβ3 or a corresponding 
control IgG and imaged using bright field microscopy. Elongated migratory cell shapes (green 
arrowheads) or spherical non-migratory cell shapes (unmarked) were detected and counted. (A) 
Representative images of AT-cells treated with IgG or α-ITGαVβ3 are shown. Bar = 50 µm (B) Proportion 
of migratory and non-migratory phenotypes of AT-cells treated with IgG or α-ITGαVβ3; n = 5, two-tailed t-
test, n.s. = non-significant. 
 
In a second experiment, we monitored AT-cells for 45 minutes after incubating them with IgG or 
α-ITGαVβ3 for 1 h. The average migration distance and velocity were calculated from all cells in 
a section. AT-cells incubated with the blocking antibody migrated significantly slowly  with an 
average velocity of 0.026 m/s  0.02 m/s compared to control cells with an average velocity of 
0.038 m/s  0.03 m/s (p < 0.01;Figure 4-23B). The accumulated distance also decreased 
when AT-cells were incubated with ITGV3 blocking antibody (60.6 m  49.3 m) compared 
to IgG treated cells (86.8 m  65.5 m; p < 0.01; Figure 4-23A and B).  
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Figure 4-23: ITGV3 promotes migration of AT-cells in 5 days ECM culture 
Cells were cultured for 5 days on ECM and incubated for one hour with α-ITGαVβ3 or IgG. (A) Trajectory 
plots depict migration of 25 HSPCs for 45 minutes. (B) Box-and-whisker plots present accumulated 
distance and velocity of 77 HSPC migration tracks monitored for 45 minutes when pre-incubated for 1 h 
with α-ITGαVβ3 or IgG. Lines show the 25th – 75th percentiles; horizontal line represents median and plus 
indicates mean value. Cells treated with blocking AB showed less migration distance and velocity; two-
tailed t-test.; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
To identify whether the ITGV3 heterodimer also mediates migration of freshly isolated CD34+ 
cells, we performed the same experiment after a shorter period of ECM culture (24 hours). 
Interestingly, an effective inhibition of cell migration using the blocking antibody could still be 
achieved (Figure 4-24). Nevertheless, short term ECM cultured HSPC migrated less compared 
to 5 days cultured cells, which points towards ITGV3 as being an essential contact and 
migration mediating integrin in HSPCs. 
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Figure 4-24: Integrin V3 promotes migration of AT-cells on 24 h ECM culture 
Cells were cultured for 24 hours on ECM and incubated for one hour with α-ITGαVβ3 or IgG. Trajectory 
plots depict migration of 25 HSPCs for 45 minutes. Migration was reduced when cells were incubated for 
one hour with α-ITGαVβ3, compared to IgG. 
 
 SDF-1 induces migration but not adhesion  4.4.5.2
To identify whether SDF-1 leads to migration of AT-cells as described by Lee-Thedieck et al. 
(2012), we performed trans-well migration assays with freshly isolated CD34+ cells, AT-cells, 
and SN-cells. We found that 20.1 ± 3.4% of freshly isolated cells actively migrated towards SDF-
1 containing medium while the spontaneous migration rate was 3.6%  1.8% (Figure 4-25A); 
these observations are in line with previously reported findings (Jacobi et al., 2010). AT- and SN-
cells, however, significantly differed in their potential to migrate towards SDF-1: while 16.9  
1.1% of AT-cells were found to migrate within 3 h, only 9.9  1.1% of SN-cells reached the 
bottom chamber (p < 0.01). Spontaneous migration was measured to be less than 3.5% in AT- 
and SN-cells (Figure 4-25A). Therefore, we conclude that CXCR4 polarization and 
receptor/ligand internalization, as presented above, are associated with AT-cell migration along 
the ECM scaffold. Further, the cells maintain and translate this capacity to follow a chemokine 
gradient as effective as freshly isolated cells. However, SDF-1 is not directly associated with 
adhesion to our ECM scaffolds, as seen upon the exogenous addition of recombinant SDF-1 
(Figure 4-25B). 
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Figure 4-25: Trans-well migration along a SDF-1 gradient and cell-matrix adhesion  
(A) Proportion of migrated freshly isolated-, SN- or AT-cells in a trans-well migration assay towards SDF-1 
containing medium (with SDF-1) or towards SDF-1 free medium (spontaneous migration, w/o SDF-1); 
n = 4, two-tailed t-test; + = significant when compared to corresponding w/o SDF-1. (B) Proportion of cells 
adhering to ECMs in medium alone or medium containing additional exogenous SDF-1; n = 3, two-tailed t-
test. Error bars denote SD; *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 Targeted modulation of ECM scaffolds  4.5
Multiple proteins incorporated into the BM-ECM regulate HSPC maintenance, proliferation, and 
maturation (Hergeth et al., 2008). However, the degree of influence of distinct ECM components 
still remain unclear. Cell-free ECMs derived from SCP-1 cells provide a suitable model system to 
identify the effect of individual protein components on HSPCs. To investigate cell-specific 
crosstalk, we aimed to reduce specific proteins of the ECM scaffolds derived from SCP-1 cells 
using RNA interference. The modified scaffolds were then used to culture HSPCs to identify 
cellular alterations in terms of proliferation and adhesion capacity.  
The extracellular matrix protein fibulin-1 is known to reduce adhesive structures for HSPCs on 
FN and to regulate HSPC proliferation and differentiation in the BM (Hergeth et al., 2008). 
Therefore, fibulin-1 expression was initially analyzed. Using immunofluorescence staining, we 
identified fibulin-1 in the perinuclear region of SCP-1 cells (Figure 4-26A, white arrowhead) and 
in the intercellular space (Figure 4-26A, yellow arrowheads), indicating its incorporation into the 
ECM. Interestingly, osteogenic differentiation of SCP-1 cells increased the expression of fibulin-1 
(Figure 4-26A upper panel compared to Figure 4-26B), as reported by Zachos et al. (2006) for 
primary MSCs. 
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Figure 4-26: Fibulin-1 in SCP-1 cells cultured in osteogenic differentiation medium and DMEM 
alone 
SCP-1 cells were grown to confluency and incubated for 7 days in osteogenic differentiation medium or 
DMEM alone. Immunostaining for α-fibulin-1 (red), f-actin (green), and nuclear counterstaining using DAPI 
(blue) were performed. (A) Representative confocal microscopy images of osteogenic medium SCP-1 
cells showed intra- (perinuclear; white arrowhead) and extracellular (yellow arrowheads) fibulin-1 
expression. Bar = 100 µm (upper panel), 25 µm (lower panel). (B) Representative confocal microscopy 
images of DMEM treated SCP-1 cells showed intra- and extracellular fibulin-1 expression but to a lower 
extend compared to osteogenic medium cells. Bar = 100 µm. 
 
Due to the formation of anti-adhesive sites in the ECM, we hypothesized that lower expression 
of fibulin-1 in the decellularised ECM-scaffolds might enhance AT-cell number and HSPC 
lodging. 
4.5.1 Fibulin-1 knock down in SCP-1 cells 
To prove our hypothesis, SCP-1 cells were transduced with lentivirus-based shRNA vectors 
targeting fibulin-1 with puromycin resistance as the selection marker. An empty vector (Ke) was 
used as control, while shRNA vectors 10 (K10) and 11 (K11), which differ in target sequence 
identity, were transduced into SCP-1 cells to generate Fibulin-1 knock down clones. As 
osteogenic differentiation increases the expression of fibulin-1 in SCP-1 cells, we used 
osteogenic differentiation medium or DMEM alone to verify knockdown efficiency. As shown by 
semi-quantitative PCR, fibulin-1 expression was not affected when cells were transduced with  
control vector (Ke) or when cells were untransduced (WT). Contrarily, SCP-1 cells transduced 
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with shRNA vectors K10 and K11 showed reduced expression of all fibulin-1 splice variants. In 
WT and Ke transduced SCP-1 cells, fibulin-1A expression was the lowest, fibulin-1B and -1D 
showed similar expression levels, while fibulin-1C expression was the highest. Identical 
expression ratios were observed in osteogenically-induced SCP-1 cells, but as indicated above 
WT and Ke transduced SCP-1 cells showed stronger band intensity and therefore increased 
expression (Figure 4-27A and B). Thisclearly demonstrats that shRNA vectors used (K10 and 
K11) were capable of downregulating fibulin-1 mRNA expression across all splice variants in 
both undifferentiated and osteogenically- differentiated SCP-1 cells. 
 
Figure 4-27: Fibulin-1 mRNA knockdown in SCP-1 cells 
Representative agarose gel electrophoresis of PCR products derived from amplification of all fibulin-1 
splice variants, fibulin-1A (F1A), -B (F1B), -C (F1C), and -D (F1D) using (A) DMEM alone and (B) 
osteogenic differentiation medium. GAPDH was used as reference gene for normalization of DNA content. 
M: GeneRuler.   
 
As RNA expression does not necessarily correlate with protein expression, the effective 
knockdown of fibulin-1 protein in ECM scaffolds derived from SCP-1 cells was quantified by 
Western Blot analyses. Before decellularization, SCP-1 cells were cultured in osteogenic 
differentiation medium to ensure high fibulin-1 expression in SCP-1 cells. Human primary MSCs 
served as control cells. Decellularized ECM proteins were separated on SDS-PAGE and 
immunoblotted with anti-fibulin-1 antibody that can recognize all splice variants. To date, no 
housekeeping protein has been reported for Western Blot analyses of proteins from ECM 
scaffolds as ECM composition is continuously altered by deposition time, differentiation stimuli, 
and media additives (Prewitz et al., 2013, 2015). Thus, as a suitable method to verfiy equal 
protein loading, we performed coomassie blue staining after SDS PAGE in parallel with the gels 
for the immunoblot. Figure 4-28A shows a representative coomassie gel staining that shows 
similar band intensities in each lane implying comparable protein loading for each sample.  
Fibulin-1 (approx. 90 kDa; Argraves et al., 1990) was incorporated into ECMs as detected by 
Western Blot analyses of proteins from ECM scaffolds derived from osteogenically differentiated 
SCP-1 cells and primary human MSCs  (Figure 4-28B). Fibulin-1 band intensity was weaker in 
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K10 and K11 transduced samples, whereas bands from WT, SCP-1 Ke, and MSC samples were 
similar in intensity (Figure 4-28B). Semi-quantitative image analysis with ImageJ confirmed 
significant reduction in band intensities for K10 and K11 compared to WT, implying successful 
knockdown of fibulin-1 expression. Further, the shRNA vector K10 was more efficient than K11 
in downregulating fibulin-1 in osteogenic induced SCP-1 cells (Figure 4-28C). 
 
Figure 4-28: Fibulin-1 protein secretion in knockdown SCP-1 cells 
(A) Representative Coomassie-stained SDS PAGE gel pcture to illiustrate equal protein loading of 
decellularized ECM. WT: wildtype, MSC: mesenchymal stromal cells, first lane: Prestain Protein Ladder 
PageRuler. (B) Western blot analyses of decellularized ECM proteins derived from SCP-1 WT, -Ke, -K10, 
-K11 and primary human MSCs using anti fibulin-1 antibody. All cells were cultured in osteogenic 
differentiation medium. Decellularized ECM proteins show reduced band intensities for K10 and K11, 
while band intensities were similar among wildtype (WT), Ke, and MSC samples. (C) Semi-quantitative 
analysis of Western Blot band intensities using ImageJ; n = 3, two-tailed t-test. Error bars denote SD; *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
To verify that the knock down (KD) procedure did not lead to alterations in cell character, 
including due to selection medium treatment, we analyzed surface marker expression and SDF-
1 secretion in SCP-1 cells under WT and KD conditions.  
The maintenance of surface markers suggests unaltered cell identity (Lv et al., 2014), and we 
initially analyzed SCP-1 cells for the presence of characteristic cell surface molecules: CD29, 
CD44, CD73, CD90, CD105, CD146, and CD166, as well as CD45 in intervals of one month for 
a period of three months by flow cytometry. The applied gating strategy is shown in Figure 
4-29A. Figure 4-29B provides a representative analysis of SCP-1 cells stably transduced with 
the shRNA vectors Ke, K10 and K11, and WT cells after a three-month selection culture. CD29, 
CD44, CD73, CD90, CD105, CD146, and CD166 were found to be consistently expressed on 
upto 100% of all SCP-1 cells, while CD45 was stably absent. Slightly different expression levels 
among the three cell clones, namely, SCP-1 Ke, SCP-1 K10, and SCP-1 K11 were observed but 
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was comparable to expression levels found on SCP-1 WT cells (Figure 4-29B). These findings 
indicate that shRNA transduction did not alter expression of characteristic cell surface molecules 
and therefore, did not alter cellular characteristics. 
 
Figure 4-29: Maintenance of surface molecule expression in Fibulin-1 knockdown SCP-1 cells 
(A) Representative flow cytometry gating strategy to analyze SCP-1 cell surface marker expression. 
Scatter light indicates cell population and single cells. Dead cells were excluded by DAPI staining. Right-
most plot indicates fluorescence intensity of applied fluorophores. (B) Flow cytometry analysis of indicated 
mesenchymal cell surface markers in SCP-1 cells cultured in selection medium at the three-month time 
point. No differences in surface marker expression after fibulin-1 knockdown were observed. Data are 
mean ± SEM; n=3. 
 
To further characterize SCP-1 cell function, we quantified the amount of secreted SDF-1. As 
mentioned above, SDF-1 was found to be incorporated into the ECM scaffolds derived from WT 
SCP-1 cells and could be recognized by HSPCs. To exclude alterations in HSPC-ECM 
interaction mediated by changes in SDF-1 levels rather than fibulin-1 knock down, the amount of 
SDF-1 secreted into the culture medium supernatant was measured using ELISA. SCP-1 WT, 
Ke, K10, K11, and human primary MSCs (as controls) were seeded in 6-well plates and the 
supernatant collected at indicated time points for up to 7 days. Both normal and osteogenic 
differentiation media were tested (Figure 4-30). SDF-1 accumulated in the supernatant over time 
and the highest concentrations were measured on day 7. Overall, supernatants from Ke, K10, 
K11, and WT cultures showed similar levels, regardless of fibulin-1 knockdown, implying that the 
shRNA vector transduction did not interfere with SDF-1 secretion. Furthermore, MSCs showed 
lower SDF-1 concentrations than the SCP-1 cells, and osteogenic differentiation reduced SDF-1 
secretion. Highest SDF-1 concentration in the supernatant of osteogenic differentiated SCP-1 
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cells was found after 7 days of culture and represented only one-tenth of the SDF-1 secreted 
into the supernatant of undifferentiated SCP-1 cells. In general, SDF-1 levels were found to be 
highly variable between cells and over time. However, there were no differences in SDF-1 
secretion by SCP-1 Ke, K10, and K11 cells compared to SCP-1 WT and MSCs neither in 
osteogenic nor in DMEM (Figure 4-30). These results indicate that viral transduction of SCP-1 
cells did not affect SDF-1 secretion compared to WT cells or primary MSCs  
 
Figure 4-30: SDF-1 secretion by fibulin-1 knockdown SCP-1 cells cultured in DMEM or 
orosteogenic differentiation medium. 
Cells were cultured in DMEM or osteogenic medium over a period of 7 days. Supernatant was collected at 
indicated time points and SDF-1 concentration determined using ELISA. SDF-1 secretion remained 
unaltered upon transduction with fibulin-1 KD in Ke, K10 and K11 vectors compared to WT and MSCs. 
Data are mean ± SD; n = 2 (with 3 technical replicates). 
 
4.5.2 HSPC support of fibulin-1 reduced ECM scaffolds 
To test our hypothesis that ECM with lower levels of fibulin-1 should provide enriched adhesion 
sites and thereby increase the number of AT-cells, we seeded freshly isolated CD34+ cells onto 
ECM scaffolds derived from fibulin-1 knock down SCP-1 clones. Additionally, we also 
hypothesized that HSPCs should show increased proliferation as fibulin-1 negatively regulates 
HSPC proliferation. In our preliminary experiments, we tested these premises by preparing 
ECMs from fibulin-1 KD SCP-1 cells cultured in DMEM or osteogenic differentiation media but 
we could neither detect increased cell adhesion nor increased expansion of HSPCs in either of 
these ECMs. Contrarily, on ECMs derived from SCP-1 cells under selection conditions (SCP-1 
Ke, -K10 and –K11), we found slightly decreased expansion rates of HSPCs compared to 
corresponding WTs (Figure 4-31). Most interestingly, the ECM derived from osteogenic 
differentiated SCP-1 WT cells was able to more efficiently and signfincatly expand HSPCs 
compared to all other conditions while ECMs derived from osteogenic differentiated SCP-1 cells, 
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under selection conditions, showed least HSPC expansion (Figure 4-31). Nevertheless, under all 
conditions tested, we observed better HSPC expansion compared to classical PCD expansion 
culture (Figure 4-31).      
 
Figure 4-31: HSPC expansion on fibulin-1 KD ECM 
HSPCs were seeded onto ECMs derived from DMEM or osteogenic differentiated SCP-1 cells under 
conditions required for fibulin-1 KD selection (SCP-1 Ke, -K10 and –K11) or WT conditions. Ke served as 
empty shRNA-vector transduction control. WT corresponds to untransduced SCP-1 cells. Expansion, 
either on ECM or PCD culture, was monitored for 5 days. Fold change in relation to starting cell numbers 
(black line) is displayed. AT-cells are shown as percentage share of counted cells; n = 3, error Bars 
denote S.D, two-tailed t-test, + = significant compared to WT osteo ECM, *p < 0.05, **p < 0.01, ***p < 
0.001. 
 
Taken together, our findings suggest that a small proportion of approximately 20% freshly 
isolated PB CD34+ HSPCs are capable of adhering (AT-cells) to SCP-1 derived BM mimetic 
ECM scaffolds while 80% of these freshly isolated HSPCs remain in the supernatant (SN-cells). 
ECM scaffolds show native macromolecular structure, can store SDF-1 secreted by SCP-1 cells, 
and release it as required. This naïve phenotype promoted signficant HSPC expansion and 
permitted greater AT-cell proliferation compared to SN-cells or classical PCD cultures. Further, 
cellular adhesion leads to morphological and mechanical adaptation of HSPCs towards a 
migrative phenotype that is predominantly mediated through surface expression of ITGαIIb, 
ITGαV and ITGβ3, common RGD receptors. Random migration along the scaffold fibers was 
induced by SDF-1 recognition through the CXCR4 receptor on HSPCs and inhibition of a single 
RGD receptor (ITGαVβ3) reduced HSPC random migration. These observations show that ECM 
scaffolds provide a naïve environment for HSPCs, and that adhesion to these structures 
promotes morphological, and functional adaptation mediated by ITGβ3 signaling. Nevertheless, 
we failed to decipher the role of fibulin-1, an ECM molecule covering adhesion sides on FN 
within the ECM scaffolds. Fibulin-1-reduced ECM scaffolds, generated by shRNA knock down in 
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SCP-1 cells, should have exhibited more adhesion sides and, therefore, should have lead to 
increased cellular adhesion.  
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5 Discussion 
The extracellular matrix is inarguably the most important cell-derived protein network for 
maintaing tissue stability. Every cell is surrounded by a tissue- and organ-intrinsic ECM, and is 
therefore, literally, connected to all other cells. Within the BM, HSPCs reside in close association 
with different cell types that are tightly anchored to an ECM scaffold which is a highly 
crosslinked, insoluble fibrillary structure composed of multiple proteins including fibronectins, 
collagens, proteoglycans, and laminins (Klein, 1995; Lee-Thedieck et al., 2012; Hynes, 2014). 
Besides structural integrity and biomechanical cues, the ECM can store and release growth 
factors and cytokines to generate morphogen gradients, which then regulate HSPC fate and 
determine tissue specificity. Moreover, the ECM composition provides certain unique 
biomechanical features that are sensed by adhesion receptors on HSPCs, transduced into 
intracellular signaling, and are thought to regulate stem cell function. As the ECM is synthesized 
and secreted by all cells in the BM niche, this regulation occurs in a bi-linear fashion, i.e., both 
from the ECM to the cells and vice versa, resulting in a highly dynamic ECM network. 
Furthermore, cell-secreted proteinases degrade ECM proteins in a highly specific manner to 
facilitate cell migration, structural remodeling, and growth factor release (Daley et al., 2008). 
These specific ECM properties enable and guide regulatory cell-cell and cell-matrix 
communications and highlight the role of the ECM as a key player in the functional regulation of 
hematopoietic stem and progenitor cells (HPCs) in BM tissue homeostasis.  
However, the state-of-the-art HSPC ex vivo culture techniques use serum-free media and 
conventional plastic culture dishes wherein the cells are kept in suspension without contact with 
each other or other protein structures. Additionally, cytokine cocktails are used to control HSPC 
expansion and cell fate. These unnatural culture condtions can result in undefined cell 
phenotypes and do not allow investigation of naïve HSPC regulation, as occuring in vivo. To 
gain a better understanding of how the BM-niche ECM regulates HSPC expansion and cell fate, 
this thesis aimed to study the interaction between HSPCs and the extracellular compartment of 
the BM niche. We adapted a protocol published by Prewitz, et al. (2013) where BM-derived 
human MSCs were used to produce native ECM scaffolds. In this approach, the macromolecular 
protein networks were covalently anchored to culture glass-slide surfaces. Using a 
decellularization approach ensured that the ECM scaffold retained its native constitution and 
remained bioactive, for further use as HSPC expansion culture scaffold. However, as the 
primary MSC secretome is known to considerably differ from source to source and donor to 
donor (Amable et al., 2014; Kalinina et al., 2015), we used the immortalized MSC cell line, SCP-
1 cells, to obtain highly reproducible ECM scaffolds.  
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The focus of this study was to characterize the morphological and mechanical adaptation of 
HSPCs upon their culture on BM-mimetic ECM scaffolds. Furthermore, we wanted to clearly 
understand the functional changes in HSPCs due to adhesion to ECM proteins.  
 SCP-1 cells as a source for ECM scaffold production   5.1
We used ECM scaffolds derived from decellularized SCP-1 cells to mimic the hematopoietic 
stem cell niche in vitro. This mesenchymal cell line was generated from human MSCs by 
overexpressing human telomerase reverse transcriptase to facilitate immortalization. These cells 
are known to display key features of MSCs, like plastic adherence, CD73, CD90 and CD105 
surface marker expression, lack of expression of CD34, CD45, CD11b, CD19, and HLA-DR, as 
well as osteogenic, adipogenic, and chondrogenic differentiation potential (Boeker et al., 2008). 
Consequently, SCP-1 cells match the minimal criteria that define multipotent mesenchymal 
stromal cells (Dominici et al., 2006). Additionally, we found that SCP-1 monolayers support 
HSPC proliferation. Similar to Prewitz et al. (2013, 2015) we detected constant ECM production 
and successful anchorage of these ECMs to poly-octadecene-alt-maleic anhydride (POMA) and 
human fibronectin coated glass slides. In contrast, when SCP-1 cells were cultured on standard 
adherent PCD or uncoated glass slides, the ECM was not covalently anchored and it 
delaminated during decellularization. As SCP-1 cells are contact-inhibited and do not produce 3-
D structures, the corresponding ECM layers ranged between 0.1 and 5 µm in height, as 
measured by confocal microscopy. Comparable covalently linked ECMs derived from human 
MSCs were demonstrated to have an average height of 1 µm, and compliance of these scaffolds 
was tested to be approximately 100 Pa (Prewitz et al., 2013, 2015), which matches BM stromal 
properties (Jansen et al., 2015). Importantly, these ECMs were able to support expansion, 
multilineage differentiation, and cytokine secretion in re-plated primary human MSCs (Seib et al., 
2009b; Prewitz et al., 2013). Furthermore, ECM scaffolds were also able to maintain and 
enhance the expansion and engraftment potential of HSPCs upon transplantation into 
immunodeficient NSG mice (Prewitz et al., 2013). To exclusively elucidate the role of niche-
mimetic ECM scaffolds in HSPC regulation, it is necessary to exclude donor-dependent 
variations in the MSC secretome (Kalinina et al., 2015). As SCP-1 cells derive from a single 
mesenchymal stromal cell, it is reasonable to assume that the secretome remains constant over 
time in culture and from passage to passage. Therefore, SCP-1 cells represent a powerful tool to 
produce standardized and highly reproducible ECMs. 
After seeding 1 x 104 HSPCs/cm² on SCP-1-derived ECM, we found that a majority of HSPCs 
remained suspended in the culture medium while the other HSPCs adhered to the provided 
ECM scaffolds. The non-adherent cells were labelled as the supernatant fraction (SN-cells) and 
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the adherent cells were identified as the attached fraction (AT-cells). After a culture period of 
12 h, an equilibrium between these two feactions was established wherein 20% of HSPCs were 
able to primarily adhere to the ECM preparations and 80% remained suspended. This finding 
might reflect an induced loss of adhesion molecules due to G-CSF mobilization as the HSPCs 
were collected from G-CSF mobilized PB (Mohle et al., 1995; Hall and Antonio, 2001). Total 
nucleated cell (TNC) and CD34+ HSPC expansion in the SN- and AT- fraction was enhanced by 
ECM scaffolds and is probably due to the presentation and release of growth factors. 
Interestingly, AT-cells proliferated the most; indicating that adhesion related signaling could be a 
mediator of cell expansion. Using the BrdU assay, we found that up to 80% of the AT-cells were 
within the G0/G1 cell cycle phase. It is important to note here that HSPCs harvested from G-
CSF-mobilized PB have been previously reported to be synchronized to this cell cycle phase 
(Uchida et al., 1997). Taken together, these two facts indicate that ECM scaffolds are probabaly 
highly supportive of HSPC proliferation and have the capacity to manintain AT-cells 
synchronized in the G0/G1 phase. In addition, AT-cells showed morphological adaptations such 
as elongated cell shape and a migratory phenotype. Reichert et al. (2015) have reported similar 
findings after 7 days of HSPC co-culture with either human or murine MSCs. Thus, these 
observations point to the ECM as preliminary site of HSPC adhesion and migration in the BM 
niche.  
 Cell adhesion and focal contact formation  5.2
Cellular homing to the BM and its retention that are mainly promoted the chemokine by SDF-1 
released by MSCs (Broxmeyer et al., 2003) necessitate morphological adaptations towards a 
migratory phenotype. Circulating HSPCs recognize SDF-1 via the CXC-receptors (CXCR). 
These receptors are known to activate integrins such as LFA-1 (ITGαL), VLA-4 (ITGα4), and 
VLA-5 (heterodimer of ITGα4 and ITGβ1), which lead to endothelial adhesion and trans-
endothelial migration (Peled et al., 2000). We found that CXCR4, the most common of CXCR, 
was expressed on both SN- and AT-cells. However, in AT-cells, the CXCR4 seemed tobe 
localized within the entire cell cytoplasm, suggesting active SDF-1 turn-over with internalization 
of the receptor/ligand complex (Broxmeyer et al., 2003). We tested this internalization by 
immunostaining and demonstrate that SDF-1 was exclusively incorporated into AT-cells and not 
into SN-cells. Additionally, in AT-cells, CXCR4 was polarized towards ECM scaffolds, similar to 
findings in HSPCs and SCP-1 cell co-culture, where CXCR4 was polarized towards the 
confluent SCP-1 cell layer. These findings have been previously demonstrated only in primary 
MSCs (Giebel et al., 2004) and may indicate that SDF-1 is released by SCP-1 cells during ECM 
production, is bound by ECM proteins, and remains bio-active within the ECM scaffold after 
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decellularization. However, paradoxically, after addition of recombinant SDF-1 to the cell culture 
medium, AT-cells lost their CXCR4 polarity, and SN-cells showed internalization of the 
receptor/ligand complex, suggesting SDF-1 recognition capacity in these cells when SDF-1 was 
accessible as a solute in the medium rather than incorporated in to the ECM scaffold. Additional 
recombinant SDF-1 did not lead to adhesion of SN-cells, and therefore, did not influence the 
number of AT-cells. These observations suggest that SDF-1 induces adhesion molecule 
expression in HSPCs in vivo that leads to BM homing but not necessarily to adhesion to the BM 
stroma. However, its gradient activity still retains HSPCs in their niche. Which strengthen 
previously findings, that the adhesion capacity of HSPCs to human MSC monolayers is not 
altered when CXCR4 is blocked using a CXCR-4 antagonist AMD3100 (Jing et al., 2010). 
However, CXCR-4 blocking reduced migration in response to SDF-1 gradients in transwell 
assays. These results suggest that HSPCs recognize SDF-1 which facilitates their retention and 
migration, but does not actively regulate adhesion to BM stroma; similar observations have been 
made by others (Alakel et al., 2009). Nevertheless, incorporation of bioactive SDF-1 into the 
ECM scaffolds closely mimics the chemokine gradient present in the physiological BM niche. 
Sun et al. (2007) and Lai et al. (2009) have described that SDF-1 induces ITGV3 expression 
in prostate cancer and chondrosarcoma cells, respectively, and that this induction is dependent 
on CXCR4 signaling. In line with these observations, HSPC culture on ECM scaffolds induced 
the surface expression of ITG3 on subsets of AT-cells to levels equivalent to those observed in 
the BM and led to the subsequent enrichment of ITGV3+ cells. However, freshly isolated cells 
were predominantly ITG3-negative and this probabaly implies that ITG3 expression occurs via 
SDF-1 when HSPCs adhere to ECM proteins and come into contact with the incorporated SDF-
1. This subsequently retained HSPCs in the BM niche.  
ITG3 exclusively heterodimerizes with either integrin V or IIb to form RGD recognizing focal 
contacts (Hynes, 2002). We found that both these integrins were upregulated in AT-cells. In 
HSPCs, dimers of these ITGs have been described as markers of long-term repopulating cells 
(Umemoto et al., 2008), mediators of HSPC maintenance (Umemoto et al., 2012; Boisset et al., 
2013), and are correlated to properties of quiescent cells (Umemoto et al., 2006). By using an 
ITGV3 blocking antibody, we show a reduction in the migratory capacity of AT-cells after a 5 
day culture period, which is a key requisite for homing to or retention of HSPCs in the BM 
(Giordano and Lichtman, 1972). Within the observed time range of 5 days, ECM adhesion 
induced the surface expression of ITG3 and subsequently of the heterodimer ITGV3. 
However, we asked whether ITGV3 is indispensable for freshly isolated HSPC migration and 
whether ITGV3 promotes migratory behavior during the early stages of HSPC-ECM contact. 
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Interestingly, when cells were incubated with the anti ITGV3 antibody after a 24 h culture 
period, we detected a reduction in the migration of AT cells. This suggests that direct surface 
expression of ITG3 and establishment of migration occur when HSPCs come into contact with 
ECM scaffolds, despite the fact that ITG3 surface expression was almost absent on freshly 
isolated cells.  
  Morphological and mechanical adaptation of HSPCs 
Studies on integrins in the last few decades show that they are able to sense physical 
parameters and transduce mechanical cues into cells to regulate fundamental functions such as 
migration, proliferation, and differentiation (Peyton et al., 2007). In HSPCs, their maintenance 
and stem cell fate decisions were found to be controlled through this contact-signaling 
machinery (Prosper and Verfaillie, 2001). ECM culture induced focal contacts, necessitated 
filamentous actin association, and thereby, outside-in signaling (Zamir and Geiger, 2001) that is 
further indicated by tyr118 phosphorylation of paxillin (Nayal et al., 2006). These structures 
transduce physical cues from the substrate  into cells by recruiting other signaling molecules and 
therefore directing lineage specification (Lee-Thedieck and Spatz 2014). However, most of these 
studies were performed using single or combined protein coating on rigid substrates like glass or 
plastic or on hydrogels with different elastic moduli in the range of several kPa to GPa. Which is 
not comparable to BM stroma mechanical properties ranging from 0.24 to 25 kPa (Jansen et al., 
2015). Contrarily, the elastic modulus of our ECM scafoldds ranged between 0.05 to 0.3 kPa and 
are very similar to those of the BM (Prewitz et al., 2013). Additionally, as these ECMs consist of 
complex protein mixtures they provide various interaction partners for HSPCs. Several ITGs 
have been described as mechanosensors on HSPCs (Lee et al., 2013), however, none of these 
were found to be differentially expressed in the SN- or AT-cells. Interestingly, AT-cells adapt to 
the ECM scaffold and display a stiffer phenotype compared to SN-cells, as measured by RT-DC. 
This was also true in SCP-1 HSPC co-cultures. However, ECM-cultured and SCP-1-co-cultured 
HSPCs differed in cell size, which can be partially explained by an increase in compeitition for 
available nutrition. Thus, that extracellular stiffness transduction into intracellular tension might 
be facilitated via combinations of ITGβ3, ITGαIIb and ITGαV. Bae et al. (2014) using mouse 
embryo fibroblasts, showed that cells recognized stiff substrates (20 to 25 kPa) via focal 
adhesion kinase-cas-rac-signaling and tyr118 phosphorylation of paxillin. Moreover, this particular 
signaling cascade increased cell cycling, whereas cultivation on soft substrates (2 to 4 kPa) 
prevented cells from mitogen-stimulated cycling. Additionally, Lee-Thedieck et al. (2012) have 
demonstrated that the adhesion of HSPCs to fibronectin is greater on hard hydrogels (E > 
38 kPa) compared to soft scaffolds (E ≤ 20 kPa). They also showed that primary HSPCs 
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increased random migration in the presence of SDF-1 when cultured on hard hydrogels. 
Similarly, we demonstrate increased cycling, fast migration of up to 0.1 µm per second, and 
membrane associated paxillin tyr118 phosphorylation. However, ECM scaffolds are more 
compliant, as ultra-soft scaffolds like tropoelastin coatings on plastic dishes were shown to 
induce stem cell proliferation (Holst et al., 2010). Therefore, our ECM approach represents a 
more complex set-up and more closely resembles the in vivo situation. This hypothesis is 
supported by the detection of incorporated chemokines like SDF-1 with the ECM scaffold and 
the provision of an extremely soft environment with its associated consequences on 
mechanotransduction. In contrast, thin ECM layers (1 µm in height) might not prevent the 
recognition of the stiff underlying glass slides and this stiffness can induce differentiation and 
migration. Therefore, a combination of hydrogels with different elastic moduli coated with 
decellularized ECMs could provide detailed insights into mechanosensing of HSPCs in a native 
BM ECM environment, complete with storage of growth factors and other signaling molecules.  
 HSPC multilineage potential 5.3
Arguably, ITG3 expression could be a marker for commitment as it is predominantly expressed 
during megakaryopoiesis (Naik and Parise, 1997; Ficko, 2008) and erythropoiesis (Ferkowicz et 
al., 2003). Moreover, ITG3 is essential for acute myeloid leukemia (AML) progression in mice 
(Miller et al., 2013). Due to increased HSPC proliferation after adhesion to ECM scaffolds, 
malignant transformation could not be excluded and needs to be carefully elucidated in detail.  
We tested potential lineage bias by comparing freshly isolated HSPCs from the BM and PB with 
HSPCs (AT-cells and SN-cells) after 5 days of culture on ECM scaffolds. Using CFU-GEMM 
assay, we found that freshly isolated BM HSPCs form significant less colonies compared to all 
other tested cell types. This is surprising as adult BM CD34+ cells were found to be the most 
potent HSPC population in terms of colony formation in all HSPC lineages compared to PB or 
cord blood cells (Wu et al., 1999); though we only tested myeloid colony formation. Most 
interestingly, ECM-cultured cells, and especially AT-cells, were found to form increased amounts 
of erythroid colonies while the formation of other myeloid lineages was not altered. A possible 
explanation for the observed increase in erythroid differentiation potential is the fact that several 
soluble and ECM incorporated factors are known to induce erythropoiesis (Lodish et al. 2010). 
Moreover, Prewitz et al. (2013) showed that pro-erythroid growth factors like IL-3 and BMP4 
(Hattangadi et al., 2011) are incorporated into primary MSC-derived ECM scaffolds.  
To identify the role of ITG3 surface expression in erythroid lineage commitment, FACS was 
used to separate CD34+ITG3+ and CD34+ITG3- cells before performing CFU-GEMM assay. 
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The number of CFUs was equal among the CD34+ITG3- PB, AT- and SN-cell populations, 
indicating that these cells are enriched in common myeloid progenitors and HSCs. Moreover, all 
cell types formed predominantly erythroid colonies, followed by CFU-Gs, CFU-Ms, CFU-GMs, 
and CFU-GEMMs; a well known phenomenon during CD34+ HSPC (Lemoli et al., 1998). Most 
interestingly, we found that sorted CD34+ITG3+ cells from ECM culture formed only erythroid 
and granulocyte colonies; however, CFU-G capacity was lower compared to CD34+ITG3- cells. 
Contrary, fresh PB derived CD34+ITG3+ cells were able to differentiate into all myeloid lineages 
but CFU-Es were also increased. Interstingly, both findings suggest that ITG3 surface 
expression on CD34+ cells is a mediator or marker of erythroid lineage commitment. However, 
HSPC adhesion via ITG3 to ECM scaffolds (AT-cells) does induce an erythroid lineage bias 
and is of significant  interest in regenerative medicine, as effective in vitro erythrocyte 
differentiation from induced pluripotent stem cells or isolated HSCs is still limited (Chang et al., 
2011). Red blood cells (RBCs) are inarguably the most important blood cells not only because of 
their number per volume of blood (10% - 45% of total blood volume), but also because of their 
physiological roles, e.g. in oxygen delivery (Kimbrel and Lu, 2011). In the US, more than 16 
million units of RBCs are collected and transfused annually into patients (Whitaker and Hinkins, 
2011) suffering mostly from anemia or trauma-induced massive blood loss. As donated RBCs 
have to match host blood group phenotype, hospitals need units of all the blood groups readily 
available for use in emergencies. This represents a logistical challenge and requires time and 
money by necessitating the storage of thousands of blood units. In this context, ECM scaffolds 
used in this study can be used to gain insights into the regulatory mechanisms of HSC erythroid 
commitment, which can further lead to translational approaches on in vitro erythrocyte 
production (Dias et al., 2011). Further, the mature “universal” type (0)Rh-negative RBCs could 
be produced in therapeutic quantities that could counter shortages in RBC supplies or even 
replace state-of-the-art RBC donation (Nakamura, 2008; Ebihara et al., 2012; Xie et al., 2014).  
 ECM scaffold modulation 5.4
In translational medicine, engineered culture substrates for efficient HSPC expansion in the 
context of tissue transplantation represent a powerful tool to overcome current limitations in 
source tissue availability. Great research efforts have been spent in generating HSPC expansion 
culture techniques including cytokine or small molecule-based approaches (Dexter et al., 1977a, 
1977b; North et al., 2007; Delaney et al., 2010; Csaszar et al., 2012; Arulmozhivarman et al., 
2016). However, in vitro HSPC suspension cultures lead to heterogeneous cell populations with 
more or less undefined phenotypes (Blank et al. 2008). This might be due to our limited 
understanding of HSPC cytokine regulation but could also be partially explained by our neglect 
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of the biophysical and structural signals that HSPCs receive within the BM niche. As discussed 
before, these signals induce cellular biochemical and biomechanical remodeling of HSPCs that 
result in functional adaptation like HSPC maintenance or commitment. Targeted modulation of 
ECM culture carriers can be used to identify cell regulation within the context of ECM signaling. 
Therefore, we induced osteogenic differentiation of SCP-1 cells during ECM production. 
Osteoblasts are MSC-derived cells that form the bone and reside mainly in the endosteal HSPC 
niche. These cells and their secreted proteins, which also facilitate ECM mineralization 
(Yamaguchi, 2014) signifcantly contribute to HSPC regulation (Taichman and Emerson, 1998; 
Visnjic et al., 2001; Calvi et al., 2003; Visnjic, 2004; Calvi, 2006). We assumed that osteogenic 
differentiated SCP-1 cells synthesize and secrete more endosteal niche related ECMs, which 
differ in amount of proteins and composition from those secreted by untreated SCP-1 cells. We 
found that osteogenic differentiated SCP-1 cells release lower amounts of SDF-1 into culture 
media, as measured by ELISA. Contrarily, SDF-1 is mainly produced by osteoblasts in vivo. This 
discrepancy can be explained by effective SDF-1 anchoring to the osteogenic ECM components 
(Jung et al., 2006; Greenbaum et al., 2013) and suggests that higher SDF-1 levels are 
incorporated into the osteogenic ECM. Interestingly, it has been shown that elevated SDF-1 
levels near the endosteal niche direct megakaryocyte relocation (Thon, 2014); thus, osteogenic 
ECMs could act as a model system for megakaryopeiesis.  
We identified increased fibulin-1 expression in osteogenic differentiated SCP-1 cells. Fibulin-1 is 
an important ECM component that regulates the adhesion of HSPCs to FN (Hergeth et al., 
2008). These findings strengthen the perception that the osteogenic ECM is variable in protein 
composition compared to other ECM scaffolds. When HSPCs were cultured in presence of ECM 
derived from osteogenic differentiated SCP-1 cells, we found increased HSPC proliferation and 
remarkably elevated amounts of TNCs after 5 days, compared to ECM derived from 
undifferentiated SCP-1 cells. However, the different ECMs did not alter the ratio of AT-cells to 
SN-cells. Thus, as the ratio is the same but the number of HSPCs was increased on osteogenic 
ECM, we found a slight but insignificant increase in the number of AT-cells per unit area, 
compared to normal ECM.  
As adhesion of HSPCs to ECM scaffolds induces morphological and biomechanical, and 
therefore, functional adaptions, we aimed to increase the number of HSPCs directly anchored to 
ECM scaffolds. Fibulin-1 is known to interfere with HSPC adhesion to FN and was, therefore, 
selected for targeted modulation experiments. We established lentiviral shRNA transduction 
using two clones (K10, K11) that targeted all four splice variants of fibulin-1. As controls, we 
used primary human MSCs, wild-type SCP-1 cells (WT), and an empty vector control (Ke) that 
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also transduced SCP-1 cells. Semi-quantitative PCR analyses of undifferentiated and 
osteogenic differentiated SCP-1 cells revealed efficient fibulin-1 knockdown and highlighted K10 
as the most efficient fibulin-1 silencing vector in this study. This knock down was confirmed by 
Western Blot analysis of decellularized osteogenic ECM proteins. These observations confirm 
shRNA knock down of ECM proteins in SCP-1 cells as possible targets for ECM scaffold 
modulation. However, as no housekeeping protein for decellularized ECMs is described, we 
used a second coomassie blue stained gel, treated under identical conditions, to verify equal 
loading of samples. A more efficient method would be a transfer of the coomassie stained 
proteins to a nitrocellulose membrane, as reported by Ranganathan and De 1996, but our 
attempt to repeat their protocol failed. Interestingly, we found similar levels of fibulin-1 in ECMs 
of primary human MSCs, SCP-1 cells (WT), and SCP-1 cells transduced with Ke, indicating 
similar ECM composition of MSCs and SCP-1 cells. These results demonstrate the feasibility of 
using primary MSCs to produce ECM scaffolds to obtain allegedly more ‘naïve scaffolds’; 
however, our data shows that SCP-1 cells have natural ECM composition. 
In order to strengthen this notion, MSC-like characteristics of SCP-1 cells were verified by the 
analysis of surface marker expression, as described for minimal criteria (Dominici et al., 2006). 
Stable surface marker expression indicates stable cell identity and unaltered cell phenotype (Lv 
et al., 2014). We could not detect significant differences in surface marker expression between 
WT and lentiviral transduced SCP-1 cells, all of which exhibited stable expression of MSC 
surface markers. Specifically, the high percentage of CD146- and CD166-positive cells was 
remarkable because CD146 expression is considered an indicator for multipotency (Covas et al., 
2008), while CD166 correlates with stromal cell character (Oswald et al., 2004). 
Unfortunately, we could not detect increased adhesion of HSPCs, either to ECM scaffolds 
derived from undifferentiated WT and lentivirusl transduced SCP-1 cells or to ECM scaffolds 
derived from osteogenic differentiated WT and lentivirus transduced SCP-1 cells. Contrarily, cell 
expansion decreased when HSPCs were cultured on ECMs generated by lentivirus transduced 
SCP-1 cells and shows that we cannot exclude the fact that HSPC growth and adhesion are 
related to the conditions used for ECM scaffold production. For efficient fibulin-1 knockdown in 
SCP-1 cells, we used puromycin as the selection agent (Moffat et al., 2006). Puromycin is a very 
efficient antibiotic agent and the transduced cells should be resistant to the drug. It is possible 
that puromycin was integrated into ECM scaffolds. Under such conditions, HSPCs are exposed 
and susceptible to ECM-incorporated puromycin, which can also affect proliferation rate. 
Therefore, we were not able to elucidate the exact role of fibulin-1 within the ECM scaffold. 
Nevertheless, the importance of native-derived ECMs for in vitro HSPC culture has been further 
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invigorated by our experiments, as HSPC expansion remained higher compared to PCD 
suspension cultures.  
Various components of the niche environment regulate hematopoiesis, maintain HSPCs within 
the bone marrow microenvironment, and give rise to several niches that increase overall 
complexity. We show that ITGβ3 surface expression is induced on HSPCs to an extent present 
in the BM using mechano-biological aspects and ex vivo biochemical cues from BM-mimetic 
ECM scaffolds derived from SCP-1 cells. Such ECMs, to the best of our knowledge, never been 
described in suspension cultures and indicate the feasibility of mimicing the BM niche 
environment. Integrin ITGβ3 was found to anchor HSPCs to ECM proteins that resulted in a 
migratory phenotype. The topographical and mechanical parameters of ECM scaffolds might be 
transduced through an outside-in signaling pathway via ITGαVβ3 that ultimately result in 
mechanical and functional adaptation of HSPCs. Such adaptation could be demonstrated by 
increased SDF-1 recognition and chemotactic migration. Further, ECM tension transduction 
through focal adhesion contacts was found to positively affect HSPC commitment, highlighting 
the importance of in vitro stroma modeling with respect to effective HSPC expansion and 
targeted lineage commitment in the context of regenerative medicine. Unfortunately, preliminary 
attempts to enhance HSPC-ECM interaction by uncovering cell adhesion sides within the 
macromolecular protein network via fibulin-1 knock down have failed. However, using targeted 
ECM modulation, either as an educated or unbiased approach, will help decipher HSPC-ECM 
interplay and elucidate ECM signaling in cell regulatory networks. This would allow a detailed 
study of signaling domains, adhesion ligands, and elasticity, to decipher the multitude of cell 
regulatory pathways derived from ECM contact. Finally, targeted ECM modulation will also 
increase the knowledge on design potentials for new biomaterials and accelerate the efficiency 
of cellular therapies in regenerative medicine.   
 
Summary 
 
83 
6 Summary 
As graft source for lymphoma or leukemia treatment, hematopoietic stem and progenitor cells 
(HSPCs) have been the focus of translational medicine for decades. HSPCs are defined by their 
self-renewing capacity and their ability to give rise to all mature blood cells. They are found 
anchored to a specialized microenvironment in the bone marrow (BM) called the hematopoietic 
niche. HSPCs can be enriched by sorting them based on the presence of the surface antigen 
CD34 before clinical or tissue engineering use. As these cells represent a minority in most graft 
sources and the amount of applicable cells is limited, ex vivo expansion-cultures were 
established using cytokine cocktails or small molecules. However, in vitro culture of HSPCs as 
suspension-cultures result in heterogeneous cell populations with undefined cellular identities. In 
the BM niche, HSPCs are not exclusively maintained by cytokines but also by cell-matrix 
adhesions mediated by integrins (ITGs). Thus, β1 and β2 ITGs were found to promote initial 
contact of HSPCs with mesenchymal stromal cells (MSCs) and ITGβ3 expression was shown to 
be a marker for long-term repopulating HSPCs in vivo. Consequently, ex vivo remodeling of the 
BM niche using co-cultures of HSPCs and niche cells like MSCs came into spotlight and was 
proven to be a promising tool for stem cell expansion. However, in clinical and research 
applications, direct contact of two cell populations necessitates HSPC post-culture purification.  
To address these problems, we established a novel culture method for remodeling the BM extra 
cellular stroma in vitro wherein we used decellularized extracellular matrix (ECM) scaffolds 
derived from immortalized mesenchymal stromal cells (SCP-1). Such scaffolds were found to be 
highly reproducible and served as in vitro niche for HSPCs by being more effective for the 
expansion of CD34+ cells, compared to classical suspension cultures. ECMs were shown to 
consist of multiple proteins including fibronectins, collagens, and a major niche chemokine 
responsible for BM homing and retention of HSPCs in vivo, namely, stromal derived factor 1 
(SDF-1). SDF-1 is known to be secreted by MSCs and is anchored to matrix proteins. This 
reveals that ECM scaffolds produced by SCP-1 cells are a naïve reconstructed 
microenvironment. When CD34+ cells were seeded, only around 20% of the cells adhered to the 
provided ECM scaffold. These cells recognized SDF-1 via C-X-C chemokine receptor type 4 
(CXCR-4), as shown by laser scanning confocal microscopy. Thus, adhesive sides as they are 
present in the BM niche are provided. However, CD34+ cells isolated from G-CSF mobilized 
peripheral blood of healthy donors were found to be heterogenous with respect to adhesion 
capacity. Nonetheless, it was similar to HSPC co-cultures with SCP-1 cells as feeder layer. 
Therefore, we separated and analyzed two cell fractions, the adherent (AT-cells) and the non-
adherent supernatant (SN-cells) cells.  
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Other signals provided by the BM extracellular stroma to HSPCs are physical cues that control 
HSPC fate. HSPCs sense these physical features through focal contacts and accordingly 
remodel their morphological and biomechanical properties. Using real-time deformability 
cytometry (RT-DC) to uncover biomechanical phenotypes of freshly isolated HSPCs, SN-cells, 
AT-cells, and classical suspension cultured HSPCs in plastic culture dishes (PCD) were 
analyzed. We found freshly isolated cells to be less deformable and small. AT-cells displayed 
actin polymerization to stress fibers, and exhibited a stiffer mechanical phenotype compared to 
PCD-cultured or SN-cells. This might constitute the first hint of functional adaptation. Integrins 
are known to establish mechanosensing focal contacts. Thus, we analyzed ITG surface 
expression and identified ITGαIIb, ITGαV, and ITGβ3 to be enriched on AT-cells compared to 
freshly isolated cells or SN-cells. Active integrins need to form heterodimers consisting of one α- 
and one β subunit. Interestingly, the identified ITGs exclusively interact with each other to form 
RGD peptide receptors. RGD is a tripeptide consisting of the amino acids arginine, glycine, and 
aspartic acid and was identified as an adhesion sequence within fibronectin and other 
extracellular proteins. Consequently, we could confirm an important role for ITGαVβ3 in HSPC-
ECM interaction with respect to adhesion and migration. However, we also identified ITGβ3 
expression on a subset of CD34+ cells either freshly isolated or ECM cultured cells, as a marker 
for erythrocyte differentiation. These findings demonstrate that, in vitro, the ECM compartment 
acts as a regulator of HSPC fate and portray mechanical recognition as a potent driver of 
differentiation. 
In this context, targeted modulation of ECM scaffolds could enhance cell-ECM interactions and 
accelerate stem cell expansion or differentiation. These modulations could also provide further 
insights into HSPC-niche regulation. We demonstrate that ECMs derived from osteogenic 
differentiated SCP-1 cells increase HSPC expansion but do not lead to increased cell adhesion. 
As ECM adhesion preliminary alters HSPC function, we aimed at developing ECM scaffolds with 
increased adhesion capacity. Using lentiviral transduction, we generated a stable knock down of 
fibulin-1 in SCP-1 cells. Fibulin-1 is an ECM protein known to form anti-adhesion sites with 
fibronectin. However, we failed to increase adherent cell numbers or enhance HSPC expansion 
in the fibulin-1 knock down ECMs.  
Taken together, SCP-1 cell-derived ECM protein scaffolds provide an in vitro niche for HSPCs 
capable of stem cell expansion. Integrin mediated signaling altered the biomechanical and 
functional properties of HSPCs and hints at suspension cultures as being inappropriate to study 
the physiological aspects of HSPCs. Targeted modulation of ECM scaffolds could theoretically 
generate suitable ex vivo environments with the capacity to gain detailed insight into HSPC 
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regulation within their niche. This will enhance the functionality of new biomaterials and will lead 
to improved regenerative therapies like BM transplantation. 
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7 Zusammenfassung 
Als Quelle für die Behandlung von Lymphomen oder Leukämien stehen hämatopoetische 
Stamm- und Vorläuferzellen (HSVZs) seit Jahren im Fokus der translationalen Medizin. HSVZs 
sind durch ihre Fähigkeit der Selbsterneuerung und die Bildung aller Blutzellen definiert, wobei 
sie selbst fest im Knochenmark (KM) in sogenannten hämatopoetischen Stammzellnischen 
verankert sind. Für klinische oder regenerative Zwecke können sie mit Hilfe des 
Oberflächenantigens CD34 angereichert werden. Da der Anteil von HSVZs in gesunden 
Spendern im Vergleich zu anderen Zellen allerdings verschwindend gering ist, wurden in vitro 
Kultursysteme für ihre Expansion entwickelt. Diese Systeme nutzen zumeist regulative Zytokine 
oder niedermolekulare Verbindungen um die Stammzelleigenschaften aufrechtzuerhalten. 
Jedoch sind solche Suspensionskulturen meist ineffizient und führen zur Differenzierung der 
HSVZs und heterogenen Zellpopulationen, da in der KM-Nische das Stammzellpotential nicht 
ausschließlich durch Zytokine aufrechterhalten wird. Vor allem Zell-Matrix Interaktionen spielen 
eine wesentliche Rolle für die Regulation von HSVZs. Diese Interaktionen werden durch 
Integrine (ITG) vermittelt. So konnte beispielsweise gezeigt werden, dass ITG β1 und β2 
benötigt werden um den Kontakt zu mesenchymalen Stromazellen herzustellen und ITG β3 
wurde als Marker für sich selbst erneuernde HSVZs beschrieben. Dementsprechend wurde 
versucht, durch die Ko-kultur von HSVZs und MSZs, die Stammzellnische ex vivo zu 
modellieren. Es konnte gezeigt werden, dass Kokulturen ein vielversprechendes Werkzeug für 
die Expansion von HSVZs sind, allerdings erfordern diese eine nachträgliche Aufreinigung der 
HSVZs für klinische oder experimentelle Anwendungen. 
In dieser Arbeit wurde ein neues Kulturverfahren etabliert, welches durch Dezellularizierung von 
imortalisierten mesenchymalen Stromazellen (SCP-1) die extrazellulären Bestandteile des KM-
Stromas modelliert. Hierbei bleibt die sekretierte extrazelluläre Matrix (EZM) der SCP-1 Zellen 
erhalten und kann als Substrat für die Kultur von HSVZs verwendet werden. Wir konnten zeigen, 
dass diese dezellularisierten Matrices hoch reproduzierbar sind und durch eine verstärkte 
Expansion der HSVZs im Vergleich zu klassischen Suspensionskulturen als eine in vitro Nische 
fungieren. Die EZM besteht aus verschiedenen Proteinen, unteranderem Fibronektinen, 
Kollagenen und stromal cell derived factor 1 (SDF-1). Das Zytokin SDF-1 wird im KM von MSZs 
sezerniert und in die EZM integriert. Wir konnten zeigen, dass SCP-1 sezernierte EZMs SDF-1 
enthalten, was diese damit als natürliches Mikromilieu kennzeichnet. Interessanterweise war nur 
ein kleiner Teil (ca. 20%) frisch isolierter HSVZsin der Lage an die Proteinstrukturen der SCP-1 
Matrices zu adhärieren. Fluoreszenzmikroskopische Aufnahmen verdeutlichten, dass diese 
Zellen in der Lage sind SDF-1 durch C-X-C chemokine receptor type 4 (CXCR-4) zu 
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internalisieren. Demnach werden adhäsive Bestandteile der KM-Nische durch die EZMs 
modelliert, wobei frisch isolierte HSVZs eine heterogene Zellpopulation hinsichtlich ihrer 
Adhäsionsfähigkeiten darstellt. Dieses Phänomen konnte auch in SCP-1-HSVZ Ko-kulturen 
bestätigt werden. Aus diesem Grund wurden die Zellen in zwei Gruppen eingeteilt und 
vergleichend untersucht: adhärente- (AT-Zellen) und Überstandszellen (SN-Zellen). 
Weitere wichtige Parameter die durch das KM-Stroma auf die Regulation von HSVZs wirken 
sind physikalische Eigenschaften der Umgebung. Zellen können diese durch Fokalkontakte 
wahrnehmen und ihre morphologischen und biomechanischen Eigenschaften daran anpassen. 
Die Charakterisierung der biomechanischen Eigenschaften von frisch isolierten C34+ Zellen, AT- 
und SN-Zellen sowie Zellen aus Suspensionskulturen erfolgte mit Hilfe der Echtzeit-
Deformationszytometrie (RT-DC). Frisch isolierte HSVs waren deutlich kleiner und 
undeformierbarer als SN-Zellen. AT-Zellen hingegen wiesen durch ihre starke 
Aktinpolymerisierung einen deutlich steiferen Phänotyp im Vergleich zu SN- du Zellen aus 
Suspensionskultur auf. Das zeigt deutlich, dass die biomechanischen Eigenschaften der EZM 
Umgebung von adhärenten Zellen erkannt und deren Form und Mechanik an diese angepasst 
wird. Dies könnte ein erster Hinweis auf funktionelle Unterschiede zwischen AT- und SN-Zellen 
darstellen. Integrine sind dafür beschrieben mechanosensorische Fokalkontakte zu bilden. 
Durchflusszytometrische-Analysen zeigten eine verstärkte Expression der Integrine ITGαIIb, 
ITGαV und ITGβ3 auf der Oberfläche der AT-Zellen. Da Integrine Heterodimere aus einer α und 
einer β Untereinheit formen müssen um aktiv zu sein war es interessant, dass die gefundenen 
dafür bekannt sind, exklusive miteinander zu interagieren und RGD-Motiv Rezeptoren formen. 
RGD-Motive sind Tripeptide bestehend aus Arginin, Glycin und Asparaginsäure die als zell-
adhäsive Strukturen in extrazellulären Proteinen wie Fibronektin detektiert wurden. 
Infolgedessen konnten wir zeigen das ITGαvβ3 eine entscheidende Rolle für die Adhäsion und 
für die Migration von AT-Zellen spielt. Allerdings, identifizierten wir auch die 
Oberflächenexpression von ITGβ3 auf einer Subpopulation aller CD34+ isolierter (frisch isolierte, 
AT-Zellen und SN-Zellen) Zellen als einen Marker für Differenzierung in Richtung Erythrozyten. 
Diese Ergebnisse zeigen, dass die EZM Substrate primär durch ihre biomechanischen 
Eigenschaften eine regulatorische Wirkung auf die Differenzierung von HSVZs haben.  
Daran anknüpfend könnte eine Veränderung der EZM modulare Substrate erzeugen, welche 
gezielt Einfluss auf die Proliferation und Differenzierung von HSVZs haben. Mit einer solchen 
modulierbaren Mikroumgebung könnten wichtige Einblicke in die Regulation von Stammzellen in 
ihrer Nische identifiziert werden. Wir konnten zeigen, dass Matrices osteogen differenzierter 
SCP-1 Zellen die Proliferation von HSVZs verbessern jedoch nicht die Menge an adhärenten 
Zellen verändert. Da vor allem die Adhäsion von HSZVs an die Matrix zu zellulären 
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Veränderungen führte, sollte ein EZM Substrat erzeugt werden, welches mehr 
Adhäsionsstrukturen bietet. Durch lentivirale Transduktion konnten wir einen stabilen knock 
down von Fibulin-1 in SCP-1 Zellen erzeugen. Fibulin-1 ist ein extrazelluläres Matrix Protein 
welches anti-adhäsive Komplexe mit Fibronektin bildet. Im Gegensatz dazu hatte der gezielte 
knockdown des extrazellulären Matrixproteins Fibulin-1 in den SCP-1 Zellen keinen Einfluss auf 
die Adhäsion und Proliferation der HSVZs.  
Zusammenfassend konnten wir zeigen, dass EZM Substrate von SCP-1 Zellen eine geeignete in 
vitro Nische für die effektive Expansion von HSVZs darstellen. Durch die Induktion von Integrin-
vermittelten Signalkaskaden wurde die Biomechanik und die Funktionalität der HSVZs 
verändert. Damit wurde möglicherweise gezeigt, dass Standard Suspensionskulturen für die 
Untersuchung von HSVZs ex vivo ungeeignet sind und nicht vollständig physiologische Effekte 
wiederspiegeln. Durch die gezielte Modulation der EZMs könnten ex vivo Umgebungen für 
HSVZs erzeugt werden, die genaue Einblicke in die Regulation der Zellen durch ihre Nische 
erlauben. Diese Erkenntnisse könnten zu neuen funktionellen Biomaterialen und zur 
Verbesserung von regenerativen Therapien wie beispielsweise der KM Transplantation führen.   
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